ПОЛУЧЕНИЕ И ИСПОЛЬЗОВАНИЕ КОНТРАСТНЫХ АГЕНТОВ

Изобретение относится к химико-фармацевтической промышленности и касается способа получения контрастных агентов. Изобретение заключается в способе получения многоядерных кластерных соединений путем взаимодействия карбонила металла и иода и использования этих кластеров и производных от них кластеров в диагностическом изображении. Описаны также новые многоядерные кластерные соединения, контрастная среда для диагностического изображения. Изобретение обеспечивает улучшение коэффициента эффективного качества диагноза для диагностического изображения. 6 с. и 8 з.п. ф-лы.

СПОСОБ ПОЛУЧЕНИЯ ИЗОБРАЖЕНИЯ КРОВОСНАБЖЕНИЯ МИОКАРДА

Изобретение относится к области медицины, а именно к контрастному агенту структурной формулы:где J представляет собой О; Y представляет собой углерод; K и L независимо выбраны из водорода и C-Салкила; М выбран из водорода, C-Салкилокси или C-Салкила, незамещенных или замещенныхF; Т и U вместе с атомами углерода, к которым они присоединены, образуют шестичленное ароматическое кольцо, которое незамещено или замещеноF; R, Rи Rнезависимо выбраны из водорода и фрагментаF; R, R, Rи Rявляются водородом; n=2; причем по меньшей мере одинF присутствует в структуре указанного контрастного агента и является фрагментом, обеспечивающим изображение. Изобретение также относится к применению указанного контрастного агента, композиции или диагностического набора на его основе для выявления, визуализации и/или мониторинга перфузии миокарда. Группа изобретений обеспечивает расширение арсенала диагностических маркеров для получения изображения кровоснабжения миокарда. 5 н. и 4 з.п. ф-лы, 55 пр.

Способ катетеруправляемого тромболизиса

Изобретение относится к области медицины, а именно к сосудистой хирургии. Для лечения окклюзирующего тромбоза глубоких вен голени проводят катетеруправляемый тромболизис. Обеспечивают циркулярную компрессию выше места предполагаемой пункции для прекращения венозного оттока и расширения просвета в дистальном венозном сегменте. Осуществляют визуализацию пункционной иглы в просвете заднебольшеберцовой вены под УЗИ-контролем и устанавливают интрадьюсер для введения перфорированного катетера. Способ позволяет снизить число осложнений за счет эффективного тромболизиса в венах голени. 1 пр.

МОДЕЛИРОВАНИЕ РАСПРОСТРАНЕНИЯ ФАРМАЦЕВТИЧЕСКОГО ПРЕПАРАТА И ГЕНЕРИРОВАНИЕ ПАРАМЕТРОВ ДЛЯ ИНЪЕКЦИОННЫХ ПРОТОКОЛОВ

Группа изобретений относится к медицине и может быть использована для моделирования распространения контрастного вещества у пациента. Для этого используют физиологически обоснованную фармакокинетическую модель, содержащую один нелинейный период насыщения в периферическом венозном компартменте. При этом экзогенное введение контрастного вещества определяется нелинейной функцией ввода u(t)≡=C(t)·Q(t), где C(t) является концентрацией средства усиления контрастности как функция от времени и Q(t) является скоростью потока введения контрастного вещества как функция от времени, при этом Q(t) является константой, равной заданной предельной скорости потока введения при скоростях потока введения, являющихся равными или больше, чем заданная предельная скорость потока введения. Также предложена система для моделирования распространения контрастного вещества. Группа изобретений позволяет устранить нежелательные побочные эффекты, связанные с избыточным введением контрастного вещества пациенту. 2 н. и ...

ОНКОЛИТИЧЕСКИЙ HSV-ВЕКТОР

Изобретение относится к биотехнологии. Предложен рекомбинантный онколитический вирус простого герпеса (oHSV), содержащий не-HSV-лиганд, специфичный к молекуле (белковой, липидной или углеводной детерминанте), присутствующей на поверхности клетки (такой как раковая клетка), и одну или более копий одной или более последовательностей-мишеней микроРНК, встроенных в один или более локусов гена HSV, а предпочтительно, в один или более генов HSV, необходимых для репликации HSV в нормальных (то есть, не-раковых) клетках. Изобретение может быть использовано в медицине для уничтожения опухолевых клеток с использованием oHSV. 11 н. и 39 з.п. ф-лы, 10 ил., 1 табл., 2 пр.

ГЕПАТОТРОПНОЕ МАГНИТНО-РЕЗОНАНСНОЕ КОНТРАСТНОЕ СРЕДСТВО НА ОСНОВЕ ХЕЛАТНОГО КОМПЛЕКСА ГАДОЛИНИЯ

Изобретение относится к области медицины, а именно к гепатотропному магнитно-резонансному контрастному средству, представляющему собой микросферы, оболочка которых сформирована из биоразлагаемого полимера – полилактида, а внутренний объем заполнен гельобразующим полисахаридом – крахмалом, и содержит водорастворимый хелатный комплекс на основе гадолиния Gd– динатриевую соль гадопентетовой кислоты, при этом массовое соотношение компонентов биоразлагаемый полимер:гельобразующий полисахарид:хелатный комплекс гадолиния составляет 32,3%:4,8%:62,9% соответственно. Изобретение обеспечивает более высокое содержание комплекса гадолиния в препарате, что позволяет снизить вводимую дозу и повысить контрастность получаемого изображения. 2 ил., 1 табл., 5 пр.

Способ получения вазорентгенограммы сосудистого русла рыбы

Изобретение может быть использовано для изучения морфологических особенностей архитектоники сосудистого русла рыб, при проведении фундаментальных исследований по их анатомии и сравнительной морфологии. Способ включает приготовление раствора путем смешивания разбавителя №1 завода художественных красок «Невская палитра» и художественной масляной краски из натурального пигмента «Ультрамарин желтый» компании «Звездный цвет» в пропорции 1:1. Полученным раствором заполняют сосудистое русло рыбы через хвостовую вену и проводят рентгенографию. Изобретение обеспечивает получение вазорентгенограмм сосудистого русла рыбы. 1 ил.

Способ получения нанодисперсного магнитоактивного рентгеноконтрастного средства

Изобретение относится к медицине, в частности к рентгенологии, и может быть использовано в качестве рентгеноконтрастного средства при рентгенологических исследованиях различных органов. Способ включает осаждение магнетита FeOиз раствора, содержащего соли железа (II) и железа (III), концентрированным раствором аммиака при значении рН реакционной смеси не менее 10 в присутствии стабилизатора - лимонной кислоты, взятой из расчета 0,02-0,5 моль на 1 моль образующегося по стехиометрии коллоидного FeO, который обрабатывают в автоклаве при 100°С в течение 20-30 мин, затем при 180°С в течение 12-16 часов, после чего выделяют декантацией на внешнем магните и промывают. Добавляют к полученному осадку водный раствор аммиака, затем в полученную суспензию вводят лимонную кислоту и раствор тантала во фтористоводородной кислоте при рН реакционной смеси 9-11. Обрабатывают полученную смесь в автоклаве при 100°С в течение 20-30 мин, затем при 180°С в течение 12-16 часов с получением осадка ферримагнитных ...

Композиция для рентгендиагностики на основе иодированной полимерной матрицы

Изобретение относится к области рентгенодиагностики и заключается в создании рентгеноконтрастной композиции с целью локализации патологического очага, расположенного глубоко в мягких тканях (осколочные ранения, опухолевые очаги, кисты, инородные тела, концы костных фрагментов и др.) путем нанесения меток непосредственно на поверхность тела. Композиция выполнена на основе йодированного гуанидинсодержащего полимера, синтезированного путем поликонденсации в расплаве гексаметилендиамина и гидройодидов гуанидина и дифенилгуанидина при 165-200°С в течение 4 часов с последующей очисткой переосаждением в воду, с концентрацией 30 г/дл полимера в диметилформамиде с красителем. Технический результат – получение рентгеноконтрастной композиции, представляющей собой высококонцентрированный окрашенный мазеобразный раствор, обладающий антибактериальными свойствами, имеющий высокую адгезию к живым тканям и обеспечивающий отчетливую визуализацию на рентгеновском снимке; упрощение и ускорение проведения процесса ...

ЭМУЛЬСИЯ СОПОЛИМЕРА ПОЛИТЕТРАФТОРЭТИЛЕНА

... 1. Способ получения эмульсии вода-в-растворителе, включающий следующие стадии:a. растворение сополимера тетрафторэтилена в смешиваемом с водой органическом растворителе;b. обеспечение водной фазы;c. растворение агента, содержащего одно из водорастворимого агента и гидрофобного агента; иd. объединение сополимера тетрафторэтилена с растворенным агентом таким образом, чтобы эмульсия являлась кинетически устойчивой.2. Способ по п. 1, отличающийся тем, что указанный агент представляет собой терапевтический агент.3. Способ по п. 1, отличающийся тем, что указанный агент представляет собой комплекс включения, содержащий гидрофобный агент и гидрофильный комплексообразующий агент.4. Способ по п. 1, отличающийся тем, что указанный агент представляет собой водорастворимый агент, который растворен в водной фазе.5. Способ нанесения на субстрат покрытия, содержащего эмульсию вода-в-растворителе, включающий следующие стадии:a. обеспечение эмульсии вода-в-растворителе, содержащей сополимер тетрафторэтилена ...

КОНТРАСТНЫЕ АГЕНТЫ ДЛЯ ОТОБРАЖЕНИЯ ПЕРФУЗИИ МИОКАРДА

... 1. Способ получения изображения кровоснабжения миокарда, включающий введение пациенту контрастного агента, который содержит фрагмент, обеспечивающий изображение, и соединение, выбранное из дегелина, пиридабена, пиридимифена, тебуфенпирада, феназаквина, аналога дегелина, аналога пиридабена, аналога пиридимифена, аналога тебуфенпирада и аналога феназаквина, и сканирование пациента с применением диагностического изображения. 2. Способ по п.1, отличающийся тем, что фрагмент, обеспечивающий изображение, представляет собой радиоизотоп для ядерно-магнитной томографии, парамагнитные фрагменты для применения в MRI, эхогенную группу для ультразвукового исследования, флуоресцентную группу для применения при получении флуоресцентного изображения или светоактивную группу для применения при получении оптического изображения. 3. Контрастный агент, содержащий фрагмент, обеспечивающий изображение, и соединение, выбранное из дегелина, пиридабена, пиридимифена, тебуфенпирада, феназаквина, аналога дегелина ...

КОНТРАСТНЫЕ ВЕЩЕСТВА ДЛЯ ДЕТЕКЦИИ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ

... 1. Соединение для диагностики рака предстательной железы у человека или животного, которое содержит, по меньшей мере, один направляющий модуль и, по меньшей мере, один детектируемый компонент, где направляющий модуль способен к взаимодействию со специфическим молекулярным маркером рака предстательной железы, выбранным из группы, состоящей из DD3PCA3 (DD3) и теломеразной обратной транскриптазы (TERT). ! 2. Соединение по п.1, где направляющий модуль выбран из группы, содержащей антитела, полипептиды, пептиды, пептидомиметики и низкомолекулярные органические соединения. ! 3. Соединение по п.1 или 2, где специфический маркер рака предстательной железы представляет собой TERT. ! 4. Соединение по п.3, где направляющий модуль представляет собой низкомолекулярный ингибитор TERT, предпочтительно выбранный из группы, состоящей из 3'-азидо-2',3'-дидезокситимидина, дизамещенных антрахинонов, флуоренонов, акридинов, соединений на основе тетрациклов, G-квадруплексных ингибиторов на основе порфирина и ...

Способ получения магнитоактивного рентгеноконтрастного средства

Изобретение относится к фармацевтической промышленности, а именно к способу получения магнитоактивного рентгеноконтрастного средства в виде водной дисперсии наночастиц, содержащих оксид железа FeOи оксид тантала ТаО, путем последовательного осаждения из соответствующих растворов, содержащих соединения железа либо соединения тантала, с помощью раствора аммиака в присутствии стабилизатора, при этом оксид тантала осаждают из содержащего тантал водного фторидного либо водного сульфатооксалатного раствора, при этом раствор аммиака используют в количестве, обеспечивающем рН смеси не менее 10, полученный осадок отфильтровывают и промывают водой, после чего распульповывают его в воде, к полученной водной дисперсии добавляют при перемешивании водный раствор, содержащий соль железа (II) и соль железа (III), концентрированный раствор аммиака до значения рН смеси не менее 10 и раствор олеата натрия в качестве стабилизатора; в полученную смесь, содержащую оксид тантала ТаОи оксид железа FeO, вводят ...

СПОСОБ ВЫЯВЛЕНИЯ ОЧАГОВ ВОСПАЛЕНИЯ С ПОМОЩЬЮ МЕТОДИКИ ПОЛИОРГАННОЙ СЦИНТИГРАФИИ

Изобретение относится к области медицины, а именно, к радионуклидной диагностике и может быть использовано для выявления очагов воспаления с помощью методики полиорганной сцинтиграфии. Проводят забор крови не менее 250-400 мл в первый стерильный пакет, который подвергают центрифугированию со скоростью 800 об/мин в течение времени, необходимого для осаждения эритроцитов. Переводят во второй пакет полученную в первом пакете обогащенную лейкоцитами надосадочную плазму. Осуществляют центрифугирование содержимого второго пакета со скоростью 1300 об/мин в течение времени, необходимого для получения аутолейкоцитов. Далее надосадочную плазму из второго пакета переводят в третий пакет, а эритроциты из первого пакета внутривенно возвращают пациенту. Добавляют радиофармпрепарат (РФП) в количестве 3-5 мл в аутолейкоциты, оставшиеся во втором пакете. Полученную клеточную взвесь инкубируют в течение 8-10 мин. К ней добавляют плазму из третьего пакета в количестве 10-20 мл с последующим центрифугированием ...

ПОРОШОК ЙОГЕКСОЛА И СПОСОБ ЕГО ПРИМЕНЕНИЯ

Способ радионуклидной диагностики опухолей головного мозга

СОСТАВ ГЕЛЯ ДЛЯ ЛУЧЕВОЙ ТЕРАПИИ ПОД ВИЗУАЛЬНЫМ КОНТРОЛЕМ

КОНТРАСТНЫЕ СРЕДЫ С НИЗКОЙ КОНЦЕНТРАЦИЕЙ ЙОДА ДЛЯ РЕНТГЕНОВСКОЙ ВИЗУАЛИЗАЦИИ И СПОСОБ РЕНТГЕНОВСКОЙ ВИЗУАЛИЗАЦИИ

... 1. Рентгеновская композиция, содержащая йоформинол и фармацевтически приемлемый носитель или эксципиент, где композиция содержит йод в концентрации 10-200 мг I/мл и ионы натрия в концентрации 70-120 мМ.2. Композиция по п. 1, дополнительно содержащая ионы кальция в концентрации 0,5-1,3 мМ.3. Композиция по п. 1, дополнительно содержащая ионы калия и/или магния.4. Композиция по п. 1, где общий объем для введения в организм составляет от 1 до 250 мл.5. Композиция по п. 1, где концентрация йода равна приблизительно 160 мг I/мл, концентрация натрия равна приблизительно 82 мМ и концентрация кальция равна 0,7 мМ.6. Композиция по п. 1, где концентрация йода равна приблизительно 200 мг I/мл, концентрация натрия равна приблизительно 73 мМ и концентрация кальция равна 0,6 мМ.7. Композиция по любому из пп. 1-6 для применения в способе рентгенологического исследования, включающемвведение композиции в организм;воздействие на организм дозой рентгеновского излучения;исследование организма с помощью диагностического ...

CПOCOБ ПOЛУЧEHИЯ TPИИOДБEHЗOЛЬHЫX COEДИHEHИЙ

HAUTMARKIERUNGSMITTEL.

Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel

Cascade polymer complexes contain: (a) complexing ligands of general formula (I), in which A stands for a nitrogenated cascade core of basic multiplicity a; X and Y independently represent a direct bond or a cascade reproduction unit of reproduction multiplicity x or y; Z and W independently represent a cascade reproduction unit of reproduction multiplicity z or w; K stands for a complexing agent residue; a equals 2 to 12; x, y, z and w independently represent the integers 1 to 4, provided that at least two reproduction units be different, that 16 Подробнее

VERFAHREN ZUR KRISTALLISIERUNG AUS WASSER VON (S)-N,N'-BIS[2-HYDROXY-1-(HYDROXYMETHIEL)ETHYL]-5-[(2-HYDROXY-1-OXOPROPYL)AMINO]-2,4,6-TRIIODO-1,3-BENZOLDICARBOXAMIDE

KASKADEN-POLYMER-KOMPLEXE UND IHRE VERFAHREN

KASKADEN-POLYMER-KOMPLEXE, VERFAHREN ZU IHRER HERSTELLUNG UND DIESE ENTHALTENDE PHARMAZEUTISCHE MITTEL

METHOD FOR THE DIAGNOSTIC AND THE THERAPEUTIC TREATMENT OF TUMORS AND/OR INFECTIOUS DISEASES OF ALL SORTS BY THE USE OF ALKALOID COMPOSITIONS OR THE SALTS THEREOF

Novel non-ionic 2,4,6-triiodoisophthalic acid bisamides, process for the preparation thereof and the use thereof as X-ray contrast media

... 2,4,6-Triiodoisophthalic acid bisamides of the general formula (I) in which R1 is a straight-chain or branched mono- or polyhydroxyalkyl radical, R2 is a hydrogen atom, a lower alkyl radical or R1, R3 is an optionally hydroxyl-substituted lower alkyl radical or is a hydrogen atom when R2 is a lower alkyl radical or R1, and R4 is a lower hydroxyl- or alkoxy-substituted alkyl radical, with the exception of the compound of the general formula I in which R1 is 2,3-dihydroxypropyl, R2 is hydrogen, R3 is 2-hydroxyethyl and R4 is hydroxymethyl. The described compounds are excellently tolerated contrast media for X-ray diagnosis.

Verwendung monomerer iodhaltiger Kontrastmittel in hohen Dosierungen für Röntgendiagnostik, insbesondere für die intraventionelle

Die Erfindung betrifft diagnostische oder therapeutische Zusammensetzung enthaltend ein monomeres iodhaltiges Röntgenkontrastmittel, insbesondere Iopromid für die Röntgen-unterstützte Diagnose oder Therapie für die Anwendung von hohen Dosen eines Röntgenkontrastmittels am Patienten, insbesondere bei Patienten mit eingeschränkter Nierenfunktion.

Methods

2,4,6-triiodo-3-acylaminophenylalkanoic acids and non-toxic salts thereof

The invention comprises compounds of the formula wherein R and R1 are hydrogen atoms or alkyl groups having from 1 to 4 carbon atoms, and non-toxic salts thereof. They are obtained by acylation of the corresponding triiodoaminophenylalkanoic acids (the preparation of which is described in Specifications 655,096 and 710,993) with the appropriate acid or derivative thereof such as the anhydride or acid halide and, if desired, converted to non-toxic salts. Preferably the anhydride in the presence of a strong acid such as sulphuric or perchloric acid is employed. When R1 represents hydrogen the formylation can be carried out with formic acid and acetic anhydride. Sodium, diethanolamine and methylglucamine salts are referred to. A list is given of suitable b -(2,4,6-triiodo-3-aminophenyl) propionic acid starting materials (obtainable by iodination of the corresponding phenyl derivatives) containing as alpha-substituents methyl, ethyl, propyl, isopropyl, butyl, isobutyl ...

PHYSIOLOGICALLY TOLERABLE METAL COMPLEX SALTS FOR USE IN NMR DIAGNOSIS

Imageable polymers

Cupredoxin derived transport agents and methods ofuse thereof

Use of ivabradine as diagnostic agent in the method of coronary angiography by multislice computed tompgraphy.

Use of ivabradine as diagnostic agent in the method of coronary angiography by multislice computed tomography

Cupredoxin derived transport agents and methods ofuse thereof

Method of preparation of a new product of contrast for radiological examinations.

Use of ivabradine as diagnostic agent in the method of coronary angiography by multislice computed tomography

Use of ivabradine as diagnostic agent in the method of coronary angiography by multislice computed tomography

Cupredoxin derived transport agents and methods ofuse thereof

HYDROPHOBE IODINE CONNECTION ABSTENTION LIPOSOME

PROCEDURE FOR THE PRODUCTION OF A STERILE INJECT-CASH PHYSIOLOGICAL ACCEPTABLE LOESUNG OF A ROENTGENKONTRASTMITTELS

ROENTGEN-VISIBLE DRUG DELIVERY DEVICE

RONTGENKONTRASTMITTEL

FORMULATION OF ROENTGEN CONTRAST WITH A MIXTURE FROM A JODIERTEN MONOMER AND DIMER

DIAGNOSTIC MEANS

ROENTGEN CONTRAST MEANS

CONTRAST MEANS

CASCADE-POLYMER-BOUND COMPLEXING AGENTS, THEIR COMPLEXES AND KONJUGATE, PROCEDURES FOR YOUR PRODUCTION AND THESE CONTAINING PHARMACEUTICAL MEANS.

RONTGEN KONTRASTMITTEL FUR RADIOLOGICAL INVESTIGATIONS

NICHTIONI TRI IODINE GASOLINE CONNECTIONS AND THESE CONTAINING CONTRAST MEANS.

CHIRALE CONTRAST MEANS

Roentgen contrast means

Improved methods for angiography

The discovery that contrast in blood vessels varies at cardiac frequency in magnitude and phase enables a set of processes for increasing the signal to noise ratio or equivalently the informational content of an angiogram. In this invention, the organization of cardiac frequency magnitude and phase enables equivalent information on anatomy and physiology to be obtained with less dose of injected chemical contrast agent, less x-ray dose, and/or less navigation of the injecting catheter within blood vessels. The cardiac frequency magnitude and phase is organized so that the arterial and venous subsystems of circulation have coherence at cardiac frequency. This enables processes for diagnosing deficits of circulation that involve alterations in the transit of blood from the arterial to the venous subsystems of circulation. Furthermore, the discovery of cardiac frequency magnitude and phase organization enables the design and manufacture of lighter and more portable angiography equipment.

Contrast agents

Integrin targeted imaging agents

Use of ivabradine as diagnostic agent in the method of coronary angiography by multislice computed tomography

Integrin targeting agents and in-vivo and in-vitro imaging methods using the same

The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.

X-ray imaging at low contrast agent concentrations and/or low dose radiation

The present invention relates to X-ray examinations and to the improvement of patient safety during such. More specifically the invention relates to X-ray diagnostic compositions having ultra-low concentrations of iodine. The invention further relates to methods of X-ray examinations wherein a body is administered with an X-ray diagnostic composition and irradiated with a reduced radiation dose.

Modeling of pharmaceutical propagation and parameter generation for injection protocols

A system includes a parameter generation system to determine at least one parameter for an injection procedure (for example, a parameter of an injection protocol or an imaging system parameter), the parameter generator system includes a physiologically based pharmacokinetic model to model propagation of a contrast medium injected into a patient including at least one of a non-linear saturation term in a peripheral venous compartment, at least one configurable transport delay term through at least one compartment, or an adaptation to model volumetric flow rate of blood and an effect thereof on the propagation of contrast medium after injection of contrast medium ceases. The physiologically based pharmacokinetic model can, for example, be discretizable.

X-ray visible drug delivery device

Diagnostic composition comprising plasma cations having superior safety profile

The present invention relates to a new diagnostic X-ray composition which exhibits a superior cardiac safety profile. The composition comprises a non-ionic iodinated dimer in a pharmaceutically acceptable carrier. More particularly, the invention provides a diagnostic composition comprising a Compound I, a pharmaceutically acceptable carrier, and dissolved therein a sodium compound and a calcium compound providing a sodium ion concentration of 40-50 mM and a calcium ion concentration of 0.1-0.7 mM. The invention also relates to methods of imaging using such diagnostic compositions.

Polymer particles made of polyvinyl alcohol and comprising a contrast agent for chemoembolization

Iohexol powder and method of using the same

Iohexol particles, contrast agent compositions comprising iohexol particles, methods of preparing iohexol particles, and methods of administering iohexol particles are provided herein. The iohexol particles of the present invention substantially dissolve in water within about 60 seconds when tested using Modified United States Pharmacopeia Method 641.

Anti-Ly6E antibodies and immunoconjugates and methods of use

The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.

Liposomal nanocarrier delivery system for targeting active CD44 molecule, preparation method therefor, and uses thereof

A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for diagnosing, preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.

Cascade polymer complexes method of manufacture, and pharmaceutical agents containing them

Contrast agents

6-azaindole compounds as antagonists of gonadotropin releasing hormone

Metal complexes of water soluble texaphyrins

Process for the crystallization from water of (S)-N,N'-bis{2-hydroxy-1-(hydroxymethyl)ethyl}-5-{(2-hydroxy-1-oxopropyl)amino}-2,4,6-triiodo-1,3-benzendicarboxamide

IODO TRIAMINOBENZENES

PEPTIDE COMPOSITION

PROCESS FOR MAKING A SKIN MARKER FOR DIAGNOSIS BY X-RAY TOMOGRAPHY AND NUCLEAR MAGNETIC RASONANCE IMAGING

The present invention provides a process for making a skin marker for diagnosis by X-ray tomography and nuclear magnetic resonance imaging, comprising a casting step of casting into a vessel an aqueous solution containing more than 8 wt% and not more than 20 wt% of a polyvinyl alcohol having a degree of hydrolysis of not less than 98 mol% and an average polymerization degree of not less than 1,000, a non-magnetic and X-ray radioopaque material being dispersed in a wall of said vessel, a freezing step of cooling the cast aqueous solution to a temperature of not higher than - (minus) 10.degree.C to obtain a frozen mass and a thawing step of thawing said frozen mass to obtain a hydrogel of high water content filled in said vessel.

LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF

A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for diagnosing, preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.

IMPROVED METHODS FOR ANGIOGRAPHY

The discovery that contrast in blood vessels varies at cardiac frequency in magnitude and phase enables a set of processes for increasing the signal to noise ratio or equivalently the informational content of an angiogram. In this invention, the organization of cardiac frequency magnitude and phase enables equivalent information on anatomy and physiology to be obtained with less dose of injected chemical contrast agent, less x-ray dose, and/or less navigation of the injecting catheter within blood vessels. The cardiac frequency magnitude and phase is organized so that the arterial and venous subsystems of circulation have coherence at cardiac frequency. This enables processes for diagnosing deficits of circulation that involve alterations in the transit of blood from the arterial to the venous subsystems of circulation. Furthermore, the discovery of cardiac frequency magnitude and phase organization enables the design and manufacture of lighter and more portable angiography equipment.

CROSS-LINKED RADIOPAQUE BIORESORBABLE POLYMERS AND DEVICES MADE THEREFROM

The present application provides polymer materials having the desired properties for implantation into a human or animal body, in particular, biocompatibility, biodegradability, radiopacity and mechanical properties. Methods of making such polymer materials, compositions or devices comprising such polymer materials, and uses of such polymer materials, compositions and devices are also disclosed.

2,4,6-TRIIODOISOPHTHALAMIDE DERIVATIVE

APTAMERS SPECIFIC FOR TLR-4 AND USES THEREOF

The invention relates to a nucleic acid aptamer with the capability of binding specifically to and inhibiting TLR-4, to a complex comprising said aptamer and a functional group, as well as to pharmaceutical compositions thereof. The invention also relates to uses and methods for detecting TLR-4 and to uses and methods for inhibiting TLR-4. Finally, the invention also relates to an aptamer for use in manufacturing a drug for the treatment of a pathology characterized by an increase in expression of TLR4 and/or an increase in activation of TLR-4.

COMPOSITIONS AND METHODS FOR USE IN ONCOLOGY

The present invention relates to compositions and methods for use in medical diagnostic and patient monitoring, typically in the context of therapy, in particular in the context of oncology to optimize tumor bed local irradiation. It more particularly relates to a biocompatible gel comprising nanoparticles and/or nanoparticles aggregates, wherein i) the density of each nanoparticle and of each nanoparticles aggregate is of at least 7 g/cm3, the nanoparticle or nanoparticles aggregate comprising an inorganic material comprising at least one metal element having an atomic number Z of at least 25, more preferably of at least 40, each of said nanoparticle and of said nanoparticles aggregate being covered with a biocompatible coating; ii) the nanoparticles and/or nanoparticles aggregates concentration is of at least about 1% (w/w); and iii) the apparent viscosity at 2 s-1 of the gel comprising nanoparticles and/or nanoparticles aggregates, is between about 0.1 Pa.s and about 1000 Pa.s when measured ...

ONCOLYTIC HSV VECTOR

The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.

BONE SUBSTITUTE CONTAINING A CONTRAST AGENT, METHOD FOR PREPARING SAME AND USES THEREOF

Composition pour biomatériaux, caractérisée en ce qu'elle comprend un phosphate de calcium dans lequel le rapport molaire Ca/P est compris entre 1 et 2, fritte avec un agent de contraste pour l'imagerie médicale réparti uniformément dans la masse de la composition, son procédé de préparation et ses utilisations médicales.

OBTAINING FREE IODINE IN PREPARATION OF AQUEOUS IODINE CHLORIDE BY ADDING POTASSIUM IODIDE

This invention relates generally to the preparation of non-ionic X-ray contrast agents, iohexol, ioversol, and iodixanol. It further relates to an improved method for the iodination reaction, a key step in the industrial preparation of non-ionic X-ray contrast agents. In particular, it relates to a method for producing free iodine in an aqueous solution of iodine chloride by adding minor amounts of potassium iodide.

USE OF GELSOLIN TO TREAT MULTIPLE SCLEROSIS AND TO DIAGNOSE NEUROLOGIC DISEASES

The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases.

CHELATED PSMA INHIBITORS

Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.

FOXC1 ANTIBODIES AND METHODS OF THEIR USE

In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.

FOXC1 ANTIBODIES AND METHODS OF THEIR USE

In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.

CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING

... ²²The present disclosure is directed, in part, to compounds and methods for ²imaging mycardial ²perfusion, comprising administering to a patient a contrast agent such as of ²Formula III²(see above formula) ²which comprises a compound that binds MC-1 and an imaging moiety, and scanning ²the patient ²using diagnostic imaging, such as MRI, ultrasound imaging, fluorescence ²imaging and optical ²imaging.² ...

ANTI-LY6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE

The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.

CONTRAST MEDIA

... 2046886 9011094 PCTABS00002 The invention relates to improved contrast media containing non-ionic contrast agents, e.g. non-ionic iodinated X-ray contrast agents, the improvement being achieved by incorporation of sodium at 20-60 mM/l.

DUAL FUNCTIONING EXCIPIENT FOR METAL CHELATE CONTRAST AGENTS

A novel dual functioning excipient for metal chelate contrast agents is disclosed. The present excipient, X m¢X'(L')!n, which is the calcium or zinc salt of the calcium or zinc complex of an organic ligand, enhances safety in that it is able to scavenge both free metal ions and free organic ligand.

TRIS(SUBSTITUTED PHENYL)BISMUTH DERIVATIVES

A tris(substituted phenyl)bismuth derivative of the general formula (I) or, if any, a pharmaceutically acceptable salt thereof: (I) {wherein X1 is Y1-NR1R2¢wherein Y1 is -SO2- or , and each of R1 and R2 is, independently of each other, a hydrogen atom, a C1-4 alkyl group or A-Z (wherein A is an alkylene chain which has 2-6 carbon atoms in total and may have a branch having at least two carbon atoms, and Z is OR3 (wherein R3 is SiR4R5R6 (wherein each of R4, R5 and R6 is, independently of one another, a C1-4 alkyl group or a phenyl group), a hydrogen atom or a C1-4 alkyl group) or NR7R8 (wherein each of R7 and R8 is, independently of each other, a hydrogen atom or a C1-4 alkyl group)) provided that the case where R1 and R2 are both hydrogen atoms is excepted!, (wherein R9 is a C1-4 alkyl group, and R7 is the same as defined above) or Y2-A-Z ¢wherein Y2 is an oxygen atom, S(O)n- (wherein n is an integer of 0 or 2) or (wherein R1 is the same as defined above), and A ...

CONTRAST AGENTS FOR ULTRASOUND IMAGING

Particles having an average diameter of less than about 12 microns comprising fatty acid cores encapsulatad with human serum albumin and methods for their preparation are disclosed. These materials are useful as contrast agents in ultrasonic imaging, having scattering intensities that are equivalent to or greater than those obtain from dispersed microbubbles but being much more stable, both in storage and when used in vivo, than are contrast agents based on dispersed microbubbles.

CASCADE-POLYMER COMPLEXES AND METHODS OF PRODUCING THE SAME

The proposed cascade-polymer complexes contain the following components: (a) complex-forming ligands of the general formula (I): A-{X-¢Y-(Z- < W-Kw > z)y!x}a, wherein A represents a nitrogen-containing cascade nucleus of base multiplicity a; X and Y independently of each other represent a direct bond or a cascade reproduction unit of reproduction multiplicity x or y; Z and W independently of each other represent a cascade reproduction unit of reproduction multiplicity z or w; K represents a complexing agent group; a is an integer between 2 and 12; x, y, z, and w independently of each other represent integers between 1 and 4; a condition being that at least two reproduction units are different and the product of the multiplicities must be such that 16 a.x.y.z.w 64; (b) at least 16 ions of an element of atomic number 20-29, 39, 42, 44 or 57-83; and optionally, cations of inorganic and/or organic bases, amino acids or amino acid amides. The proposed complexes are useful in diagnosis and therapy ...

X-RAY CONTRAST MEDIA

X-ray contrast media containing X-ray contrast substances coated with polymers which are capable of adhering to the digestive tract mucosal surface under acidic conditions and being liberated from the surface under neutral or alkaline conditions. The excellent adhesion of these media to the digestive tract makes it possible to lower the dose and concentration thereof.

Verfahren zur Herstellung eines Tyrosinabkömmlings.

Verfahren zur Herstellung eines Mittels zur Vorbehandlung des Dickdarmes für Röntgenaufnahmen

Verfahren zur Herstellung von N-Acylderivaten der 3,5-Diamino-2,4,6-trijod-benzoesäure

Verfahren zur Herstellung von 5-Acylamino-2,4,6-trijodisophthalsäureamiden

Compositions and methods for enhancing contrast in imaging

Examples of compositions of liposomes and methods of making the same containing high concentrations of contrast-enhancing agents for computed tomography are provided. Example compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and other tissues of the subject. Also provided are example methods for making the liposomes stable, that is, resistant to leakage of the contrast-enhancing agents, including the extrusion of the liposomes at high pressures and at high flow rates per total pore area of the extrusion filters.

Post-biopsy cavity treatment implants and methods

A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.

Optical imaging agents

The present invention relates to a method of in vivo optical imaging, of the margins around tumours, which comprises an optical imaging contrast agent. The optical imaging agents comprise conjugates of near-infrared dyes with synthetic polyethylene glycol (PEG) polymers having a molecular weight in the range 15-45 kDa. Also disclosed are optical imaging contrast agents, pharmaceutical compositions and kits.

Heart-slowing drug containing short-acting beta-blocker as teh active ingredient

The present invention relates to an agent which slows down the heart rate which has an excellent controlling ability in diagnostic imaging comprising a short-acting β-blocker (e.g. landiolol hydrochloride or esmolol hydrochloride). The short-acting β-blocker has a property of slowing down the heart rate and it can temporarily suppress the tachycardia at diagnosis. According to the dose and the method of administration, it can control the period for the heart rate adjustment. Also, the present invention relates to a diagnostic imaging auxiliary comprising a short-acting β-blocker as active ingredient.

Compositions and methods using microspheres and non-ionic contrast agents

The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.

Tumor tissue-selective bio-imaging nanoparticles

A bio-imaging nanoparticle is composed of a core nanoparticle, a bonding layer having organic ligands, surfactants and polyoxyalkylene derivatives of fatty acid ester, and veiling the core nanoparticle, and functional molecules, wherein the organic ligands are bound to a surface of the core nanoparticle, the surfactants are bound to a portion of the surface of the core nanoparticle to which the organic ligands are not bound, the polyoxyalkylene derivatives of the fatty acid ester are introduced in an empty space between the organic ligands and the surfactants of the bonding layer, and the functional molecule is bound to a second terminal end opposite to a first terminal end of both terminal ends of the organic ligand, the first terminal end of the organic ligand being bound to a shell of the core nanoparticle.

Foxc1 antibodies and methods of their use

In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.

Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use

Generally, hydrogels are prepared by forming a liquid reaction mixture that contains a) monomer(s) and/or polymer(s) at least portion(s) of which are sensitive to environmental changes (e.g., changes in pH or temperature), b) a crosslinker and c) a polymerization initiator. If desired, a porosigen may be incorporated into the liquid reaction mixture to create pores. After the hydrogel is formed, the porosigen is removed to create pores in the hydrogel. These hydrogels may be prepared in many forms including pellets, filaments, and particles. Biomedical uses of these hydrogels include applications wherein the hydrogel is implanted in the body of a patient and an environmental condition at the implantation site causes the hydrogel to expand in situ.

DELIVERY OF AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED LIPOSOMES

The invention described herein pertains to folate-receptor targeted agents comprising therapeutic agents useful for the treatment of inflammatory disease, including folate-receptor targeted liposomes (folate-targeted liposomes) containing entrapped therapeutic agents and folate-receptor targeted dendrimers conjugated to therapeutic agents (folate-targeted dendrimer conjugates), useful for the treatment of inflammatory disease, including auto-immune disease, as well as to folate-targeted liposomes containing entrapped imaging agents and dendrimer conjugates conjugated to imaging agents, for use in the diagnosis and monitoring of treatment in such disease. 1. A folate-receptor targeted agent comprising a therapeutic agent useful for the treatment of inflammatory disease which is a folate-targeted liposomal composition comprising an anti-inflammatory agent as an entrapped agent wherein the lipid bilayer is primarily composed of DSPC/cholesterol with a mol ratio of about 56:40.23-. (canceled)4. The liposomal composition of wherein the lipid bilayer comprises a comprises a folate-targeting conjugate composed of (a) a lipid having a polar head group and a hydrophobic tail claim 1 , (b) a hydrophilic polymer having a first end and a second end claim 1 , said polymer attached at its first end to the head group of the lipid claim 1 , and (c) a folate ligand (Fol) attached to the second end of the polymer claim 1 , and wherein the folate ligand is a folic acid residue or an analog or derivative thereof claim 1 , wherein the hydrophilic polymer of the folate targeting conjugate is a PEG having an average molecular weight of about 200-5000 in which the end groups claim 1 , prior to attachment claim 1 , are independently amino claim 1 , hydroxy claim 1 , thiol or carboxy; and wherein the folate targeting conjugate is present at about 0.01 mol % to about 1 mol % in the lipid bilayer.56-. (canceled)7. The liposomal composition of wherein the lipid bilayer further comprises a ...

COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS

The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The cargo compound may be a nucleic acid and specifically a DNA, RNA or anti-sense. The invention further discloses methods for treating cancer and diagnosing cancer. 1. An isolated peptide that is a variant , derivative or structural equivalent of a cupredoxin; and that can inhibit the development of premalignant lesions in mammalian tissue.2. The isolated peptide of claim 1 , wherein the cupredoxin is selected from the group consisting of azurin claim 1 , pseudoazurin claim 1 , plastocyanin claim 1 , rusticyanin claim 1 , Laz claim 1 , auracyanin claim 1 , stellacyanin and cucumber basic protein.3. The isolated peptide of claim 2 , wherein the cupredoxin is azurin.4Pseudomonas aeruginosa, Alcaligenes faecalis, Achromobacter xylosoxidan, Bordetella bronchiseptica, MethylomonasNeisseria meningitidis, Neisseria gonorrhea, Pseudomonas fluorescens, Pseudomonas chlororaphis, Xylella fastidiosaVibrio parahaemolyticus.. The isolated peptide of claim 1 , wherein the cupredoxin is from an organism selected from the group consisting of sp. claim 1 , and5Pseudomonas aeruginosa.. The isolated peptide of claim 4 , that is from6. The isolated peptide of claim 1 , which is part of a peptide selected from the group consisting of SEQ ID NOS: 1 claim 1 , 3-19.7. The isolated peptide of claim 1 , to which a sequence selected from the group consisting of SEQ ID NOS: 1 claim 1 , 3-19 has at least 80% amino acid sequence identity.8. The isolated peptide of claim 1 , which is a truncation of the cupredoxin.9. The isolated peptide of claim 8 , wherein the peptide is more than about 10 residues and not more than about 100 residues.10Pseudomonas aeruginosaPseudomonas aeruginosaPseudomonas aeruginosa. The isolated peptide of claim 8 , wherein the peptide comprises a ...

STABILIZED, BIOCOMPATIBLE GOLD NANOPARTICLES

The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from polyphenols- or flavanoids-rich plant material or reactive phytochemical components of the plant material. The gold nanoparticles of the invention can be fabricated with an environmentally friendly method for making biocompatible stabilized gold nanoparticles. In preferred embodiments, the coating consists of material from polyphenols- or flavanoids-rich plant material or reactive phytochemical components of the plant material. 1. Gold nanoparticles stabilized with a material coating of material from polyphenols- or flavanoids-rich plant material or reactive phytochemical components of the plant material.2. The gold nanoparticles of claim 1 , wherein the plant material comprises black tea.3. The gold nanoparticles of claim 1 , wherein the plant material comprises turmeric or its component curcumin.4. The gold nanoparticles of claim 1 , wherein the plant material comprises cinnamon.5. The gold nanoparticles of claim 1 , in an aqueous solution having a physiological pH.6. A method of sensing comprising introducing stabilized gold nanoparticles of into a human or animal subject and conducting gold nanoparticle enhanced imaging.7. A method of therapy comprising introducing stabilized gold nanoparticles of into a human or animal subject and conducting gold nanoparticle enhanced therapy.8. The gold nanoparticles of claim 1 , wherein the coating consists of polyphenols- or flavanoids-rich plant material.9. The gold nanoparticles of claim 1 , consisting of nanoparticles that are homogenous with a common diameter.10. The gold nanoparticles of claim 9 , wherein the common diameter is 13±5 nm. The application is a divisional application of and claims priority under 35 U.S.C. §120 from prior application Ser. No. 12/283,935, which was filed on Sep. 17, 2008, now Pat. No. ______, which claimed priority under 35 U.S.C. §119 from prior provisional application Ser. No. 60/994, ...

SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE

Alkyl cyanoacrylate compositions and methods for making those compositions, utilizing high purity monomeric starting materials, formed into more viscous oligomers, and combined with a plasticizer and inhibitor to provide a single-container, storage stable medical cyanoacrylate. 1. A medical grade composition suitable for application to or in the human body , comprising a mixture of:(a) a polymerizable alkyl cyanoacrylate oligomer, wherein said polymerizable alkyl cyanoacrylate oligomer has a viscosity of from 10 centipoise to 30 centipoise;(b) at least one polymerization inhibitor;(c) a contrast agent; and(d) a plasticizer,wherein said composition is sealed in a single container and is stable for more than one month at room temperature, and is adapted to polymerize in vivo.2. The composition of claim 1 , wherein the polymerizable alkyl cyanoacrylate oligomer is selected from the group consisting of 2-hexyl cyanoacrylate oligomer claim 1 , n-hexyl cyanoacrylate oligomer claim 1 , pentyl cyanoacrylate oligomer claim 1 , heptyl cyanoacrylate oligomer claim 1 , and octyl cyanoacrylate oligomer.3. The composition of claim 1 , wherein the polymerizable alkyl cyanoacrylate oligomer is n-hexyl cyanoacrylate oligomer.4. The composition of claim 1 , wherein the inhibitor is selected from the group consisting of 4-methoxyphenol claim 1 , 2 claim 1 ,6-di-tert-butyl-4-methylphenol claim 1 , hydroquinone claim 1 , phosphoric acid claim 1 , sulfur dioxide (SO) claim 1 , and any combination thereof.5. The composition of claim 4 , wherein the inhibitor is a mixture of 4-methoxyphenol claim 4 , 2 claim 4 ,6-di-tert-butyl-4-methylphenol claim 4 , and sulfur dioxide.6. The composition of claim 1 , wherein the plasticizer is tri-n-butyl O-acetylcitrate.7. The composition of claim 1 , wherein the contrast agent is selected from the group consisting of gold claim 1 , platinum claim 1 , tantalum claim 1 , titanium claim 1 , tungsten claim 1 , barium sulfate claim 1 , and combinations ...

Compositions and methods for treating nephropathy

Activated fatty acids, pharmaceutical composition compositions including activated fatty acids, methods for using activated fatty acids to treat nephropathy, and methods for preparing activated fatty acids are provided herein.

In-vivo gelling pharmaceutical pre-formulation

Provided herein are in vivo gelling pharmaceutical pre-formulations forming biocompatible hydrogel polymers that are polymerized in vivo and kits comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally at least one therapeutic agent. The biocompatible hydrogel polymer is bioabsorbable and releases the therapeutic agent at a target site, avoiding systemic exposure.

X-RAY IMAGING AT LOW CONTRAST AGENT CONCENTRATIONS AND/OR LOW DOSE RADIATION

The present invention relates to X-ray examinations and to the improvement of patient safety during such. More specifically the invention relates to X-ray diagnostic compositions having ultra-low concentrations of iodine. The invention further relates to methods of X-ray examinations wherein a body is administered with an X-ray diagnostic composition and irradiated with a reduced radiation dose. 1. A composition comprising an iodinated X-ray contrast agent and a pharmaceutically acceptable carrier or excipient , wherein the composition has a concentration of iodine of less than 100 mg I/ml.2. (canceled)3. A composition as claimed in wherein said X-ray contrast agent is a non-ionic iodinated monomeric claim 1 , dimeric claim 1 , trimeric claim 1 , tetrameric or pentameric compound.5. (canceled)6. A method comprisingadministering to a body a composition comprising an X-ray contrast agent and a pharmaceutically acceptable carrier or excipient, wherein said composition has a concentration of iodine of 10-170 mg I/ml,applying an X-ray radiation dose to the body wherein said radiation dose is provided by a tube voltage energy in the range of 70-140 kVp,examining said body with a diagnostic device and compiling data from said examining step.7. (canceled)8. A method as claimed in wherein said composition has a concentration of iodine of less than 150 mg I/ml.9. A method as claimed in claim 8 , wherein said contrast agent is iodinated and claim 8 , wherein said dose of radiation has an average energy spectrum substantially corresponding to the k-edge of iodine.10. (canceled)11. A method as claimed in wherein said reduced X-ray radiation dose is further provided by a tube current in the range of 5-1000 mA.12. A method as claimed in wherein said radiation dose is >30% lower than standard radiation doses.13. A method as claimed in further comprising a step of noise reduction through an advanced image reconstruction method.14. A method as claimed in wherein said noise reduction ...

Gel composition for filling a breast milk duct prior to surgical excision of the duct or other breast tissue

The invention is a gel composition for delivery to a breast milk duct prior to surgical excision of breast tissue including cancerous lesions. The invention also provides methods of mapping all or nearly all of a breast milk duct prior to surgical excision of breast tissue, and method of identifying part or all of a breast duct or ducts as a surgical aide to a breast surgeon. Kits to support these methods and including these compositions are also provided.

Quantum dot materials, methods for making them, and uses thereof

The disclosure provides quantum dot materials, compositions and methods useful in the treatment of various disorders. In particular, the disclosure provides cadmium-free and lead-free quantum dots. 2. A quantum dot material according to claim 1 , wherein Y is Se or Te.3. A quantum dot material according to claim 1 , wherein Y is Se.4. A quantum dot material according to claim 1 , wherein Y is Te.5. A quantum dot according to claim 1 , wherein x is 0.001-0.03.6. A quantum dot material according to claim 5 , wherein x is 0.01-0.03.7. A quantum dot material according to claim 1 , where the stabilizing ligand is glutathione claim 1 , thioglycolic acid claim 1 , or 3-mercaptopropionic acid.8. A quantum dot material according to claim 1 , where the stabilizing ligand is glutathione.9. A quantum dot material according to claim 1 , where the material has a fluorescence emission at a wavelength in the visible or near-infrared.10. A quantum dot material according to claim 9 , wherein the wavelength is about 620 nm to about 900 nm.11. A quantum dot material according to claim 1 , wherein the particles have an average diameter in the range of about 2 to about 15 nm.12. A diagnostic composition comprising a quantum dot material according to and a diagnostically acceptable carrier claim 1 , solvent claim 1 , adjuvant or excipient.13. A method of preparing a quantum dot material according to claim 1 , the method comprising:(a) mixing a Zn precursor, a Ag precursor, and the stabilizing ligand in a solvent;(b) adding a solution containing a Y precursor to the mixture of (a);(c) allowing the plurality of particles to form; and(d) precipitating the formed quantum dot.14. A method according to claim 13 , wherein the stabilizing ligand is glutathione claim 13 , thioglycolic acid claim 13 , or 3-mercaptopropionic acid.15. A method according to claim 13 , wherein Y is Se or Te.16. A method according to claim 13 , wherein the molar ratio of Zn precursor to Y precursor is between 10:1 and 5 ...

Medicinal preparation particularly for the treatment of slipped discs hernias

The invention concerns a product consisting in an injection medicinal formulations comprising at least one compound to provide a viscous formulation, ethanol and at least tungsten and/or tantalum metal making said formulation opaque to X rays so as to control its delivery and its action. Said formulation is in particular useful for treating herniated invertebral discs but also in intervention having demonstrated the efficacy of pure ethanol: treatment of hepatocellular tumours or osteoid osteomas, renal cysts and arterial-veinous angiomas.

CONTRAST MEDIUM COMPOSITION WITH CONTRAST ENHANCEMENT EFFECT BY COMPRISING HIGHLY CONCENTRATED CONTRAST AGENT

The present invention relates to a contrast medium composition (formulation) comprising a highly concentrated contrast agent for use in an imaging method. 1. A contrast medium composition comprising an aqueous contrast agent selected from the group consisting of iopentol , iotrolan , iohexol , ioversol , ioxilan , iodixanol and iobitridol in an amount of 360 mgI/mL to 450 mgI/mL.2. The contrast medium composition of claim 1 , wherein the aqueous contrast agent is iohexol.3. The contrast medium composition of claim 2 , which comprises the aqueous contrast agent in a concentration of 380 mgI/mL to 420 mgI/mL.4. The contrast medium composition of claim 2 , which comprises the aqueous contrast agent in a concentration of 380 mgI/mL.5. The contrast medium composition of claim 2 , which comprises the aqueous contrast agent in a concentration of 400 mgI/mL.6. The contrast medium composition of claim 2 , which comprises the aqueous contrast agent in a concentration of 420 mgI/mL.7. The contrast medium composition of claim 1 , which further comprises aqueous buffer claim 1 , sterile water for injection claim 1 , chelating agent and pH controlling agent.8. The contrast medium composition of claim 7 , wherein the aqueous buffer is tromethamine.9. The contrast medium composition of claim 7 , wherein the chelating agent is at least one selected from the group consisting of ethylenediamine claim 7 , edetate calcium disodium and edetate disodium.10. The contrast medium composition of claim 1 , whose pH is 7 to 8.11. The contrast medium composition of claim 3 , wherein CEA and CEP of the contrast medium composition comprising the aqueous contrast agent in a concentration of 360 mgI/mL to 450 mgI/mL satisfies the following relationship with CEAand CEPof the contrast medium composition comprising the aqueous contrast agent in a concentration of 350 mgI/ml.{'br': None, 'sub': '350', 'CEA>CEA'}{'br': None, 'sub': '350', 'CEP>CEP'}12. The contrast medium composition of claim 4 , wherein ...

MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS

The present invention provides targeted delivery compositions and methods of using the compositions for treating and diagnosing a disease state in a subject. 2. The targeted delivery composition of claim 1 , wherein (LPEG) is —Z—Z—Z—.3. The targeted delivery composition of claim 2 , wherein Zis W; Zis selected from an amide claim 2 , thioamide claim 2 , ester claim 2 , carbamate or urea; and Zis a PEG component having a defined length.4. The targeted delivery composition of claim 3 , wherein the subscript n is 3.5. The targeted delivery composition of claim 3 , wherein the subscript n is 2.6. The targeted delivery composition of claim 3 , wherein the subscript n is 1.7. The targeted delivery composition of claim 1 , wherein the subscript n is 0.8. The targeted delivery composition of claim 1 , wherein the amino acid is an α-amino acid.9. The targeted delivery composition of claim 8 , wherein the α-amino acid is selected from the group consisting of aspartic acid claim 8 , glutamic acid claim 8 , lysine claim 8 , arginine claim 8 , and glycine.10. The targeted delivery composition of claim 9 , wherein the α-amino acid is selected from the group consisting of glutamic acid and lysine.12. The targeted delivery composition of claim 1 , wherein said nanocarrier is selected from the group consisting of a liposome claim 1 , a micelle claim 1 , a lipid-coated bubble claim 1 , and a block copolymer micelle.13. The targeted delivery composition of claim 1 , wherein said nanocarrier further comprises a stealth agent.14. The targeted delivery composition of claim 1 , wherein said nanocarrier comprises a therapeutic agent selected from the group consisting of doxorubicin claim 1 , cisplatin claim 1 , oxaliplatin claim 1 , carboplatin claim 1 , 5-fluorouracil claim 1 , gemcitibine and a taxane.15. The targeted delivery composition of claim 1 , wherein said attachment component is a lipid.16. The targeted delivery composition of claim 1 , wherein (LPEG) has the formula:{'br': None ...

Apoptosis imaging agents based on lantibiotic peptides

The present invention relates to radiopharmaceutical imaging in vivo of apoptosis. The invention provides imaging agents which target apoptotic cells via selective binding to the aminophospholipid phosphatidylethanolamine (PE), which is exposed on the surface of apoptotic cells. The radiopharmaceuticals comprise radiometal complexes of chelator conjugates of PE-binding peptides. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.

METHODS AND COMPOSITIONS FOR OBJECTIVELY CHARACTERIZING MEDICAL IMAGES

Methods and compositions are provided for objectively characterizing a pathological lesion in a patient. The method comprises: introducing into the patient a contrast enhancing agent; subjecting the patient to at least one of magnetic resonance imaging and computed tomography to obtain an image; and applying a 3-D autocorrelation function to a subdomain of interest of the image to obtain at least one 3-D autocorrelation spectrum. The method may further comprise comparing the at least one 3-D autocorrelation spectrum to a pre-existing 3-D autocorrelation spectrum that is characteristic for the pathological lesion. In one example, the methods and compositions may be useful for identifying and objectively characterizing amyloid plaque deposits characteristic of Alzheimer's Disease. 1. A method for characterizing a pathological lesion in a patient , the method comprising:introducing into the patient a contrast enhancing agent;subjecting the patient to at least one of MRI and CT to obtain an image; andapplying a 3-D autocorrelation function to a subdomain of interest of the image to obtain at least one 3-D autocorrelation spectrum.2. The method of claim 1 , further comprising comparing the at least one 3-D autocorrelation spectrum to a pre-existing 3-D autocorrelation spectrum that is characteristic for the pathological lesion.3. The method of claim 1 , wherein the subjecting comprises subjecting the patient to MRI.4. The method of claim 3 , wherein the contrast enhancing agent comprises: a phospholipid;', 'a phospholipid that is derivatized with a polymer; and', 'cholesterol,', 'wherein the liposomes at least one of encapsulate and chelate gadolinium compounds., 'liposomes, the liposomes comprising5. The method of claim 3 , wherein the contrast enhancing agent comprises: DPPC;', 'Gd-DTPA-BSA;', 'cholesterol; and', 'mPEG2000-DSPE., 'liposomes, the liposomes comprising6. The method of claim 3 , wherein the contrast enhancing agent comprises a GdDTPA chelate derivative ...

X-ray visible medical device and preparation method thereof

The present invention relates to an X-ray visible medical device comprising a medical device and a layer bound onto the medical device, wherein the layer is composed of an X-ray contrast material or a composite of the X-ray contrast material and a biocompatible polymer. Also disclosed is a method for preparing the X-ray visible medical device.

NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER

The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions. 153.-. (canceled)54. A method of treating a subject in need comprising administering or applying a nanoparticulate active agent composition comprising:(a) at least one active agent having an effective average particle size of less than about 2000 nm; and(b) lysozyme adsorbed on or associated with the surface of the active agent.55. The method of claim 54 , wherein the at least one active agent is selected from the group consisting of a drug claim 54 , vitamin claim 54 , herb claim 54 , cosmetic agent claim 54 , coloring agent claim 54 , flavor agent claim 54 , fragrance agent claim 54 , sunscreen claim 54 , moisturizer claim 54 , deodorant claim 54 , hair conditioner agent claim 54 , hair dye claim 54 , hair spray agent claim 54 , hair cosmetic agent claim 54 , hair cleanser agent claim 54 , and depilatory agent.56. The method of claim 54 , wherein the at least one active agent is selected from the group consisting of proteins claim 54 , peptides claim 54 , nutraceuticals claim 54 , carotenoids claim 54 , anti-obesity agents claim 54 , corticosteroids claim 54 , elastase inhibitors claim 54 , analgesics claim 54 , anti-fungals claim 54 , oncology therapies claim 54 , anti-emetics claim 54 , analgesics claim 54 , cardiovascular agents claim 54 , anti-inflammatory agents claim 54 , anthelmintics claim 54 , anti-arrhythmic agents claim 54 , antibiotics claim 54 , anticoagulants claim 54 , antidepressants claim 54 , antidiabetic agents claim 54 , antiepileptics claim 54 , antihistamines claim 54 , antihypertensive agents claim 54 , antimuscarinic agents claim 54 , antimycobacterial agents claim 54 , antineoplastic agents claim 54 ...

Radiopaque shape memory polymers for medical devices

Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include shape memory polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional iodinated monomer and a second repeating unit derived from a multifunctional non-iodinated monomer wherein neither of the two monomers is fluorinated. Devices formed from radiopaque polymer compositions are also provided.

Therapeutic Angiogenesis for Treatment of the Spine and Other Tissues

Methods for the diagnosis and treatment of ischemic spinal conditions, degenerative disc disease, back pain and/or other tissue pathologies. Patients with ischemic spine disease can be categorized into subsets that are deemed to have potential to respond to therapy. In particular, therapies are disclosed which involve stimulation of neovascularization so as to increase perfusion of spinal and other anatomies. 1. A method of diagnosing a patient with an ischemic spinal disorder , comprisingobtaining electronic image data of one or more vertebral bodies of the patient;identifying one or more regions of interest in the electronic image data, the one or more regions of interest including electronic image data of at least a portion of an intravertebral microcirculation proximate to an intervertebral endplate;analyzing the one or more regions of interest to obtain one or more perfusion measurements within each region of interest;comparing the one or more perfusion measurements with a predetermined perfusion value; anddiagnosing said patient with said ischemic spinal disorder wherein said one or more perfusion measurements is below said predetermined perfusion value.2. A method of treating a patient having an ischemic spinal disorder comprising:obtaining one or more images of at least a portion of a spine of the patient;analyzing the one or more images with a computing system to quantify a localized perfusion of the intravertebral microcirculation proximate to one or more endplates of one or more intervertebral discs of the patient's spine;identifying at least one intravertebral location where the quantified localized perfusion of the intravertebral circulation indicates hypoperfusion of the intravertebral circulation; andtreating the patient by injecting an angiogenesis inducing compound proximate to the at least one intravertebral location where the quantified localized perfusion of the intravertebral circulation indicates hypoperfusion of the intravertebral circulation. ...

USE OF GELSOLIN TO TREAT MULTIPLE SCLEROSIS AND TO DIAGNOSE NEUROLOGIC DISEASES

The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases. 1. A method for characterizing a subject's risk profile of developing a future neurologic disease , comprising:obtaining a level of gelsolin in the subject,comparing the level of the gelsolin to a predetermined value, andcharacterizing the subject's risk profile of developing a neurologic disease based upon the level of gelsolin in comparison to the predetermined value, wherein a level of gelsolin at or below the predetermined level is indicative that the subject is at an elevated risk of developing the neurologic disease, and wherein a level of gelsolin at or above the predetermined level is indicative that the subject is not at an elevated risk of developing the neurologic disease.2. The method of claim 1 , wherein the neurologic disease is a demyelinating disease.3. The method of claim 1 , wherein the neurologic disease is multiple sclerosis.4. The method of claim 3 , wherein the multiple sclerosis is acute claim 3 , relapsing claim 3 , remitting claim 3 , stable claim 3 , chronic claim 3 , or probable.5. The method of claim 1 , wherein the neurologic disease is acute disseminated encephalomyelitis claim 1 , transverse myelitis claim 1 , progressive multifocal leukoencephalopathy claim 1 , adrenoleukodystrophy claim 1 , adrenomyeloneuropathy claim 1 , central pontine myelinolysis claim 1 , optic neuritis claim 1 , neuromyelitis optica (Devic's syndrome) claim 1 , Leber's hereditary optic neuropathy claim 1 , tropical spastic paraparesis (HTLV-associated myelopathy) claim 1 , or Guillain-Barré syndrome (also called acute inflammatory demyelinating polyneuropathy claim 1 , acute idiopathic polyradiculoneuritis claim 1 , acute idiopathic polyneuritis claim 1 , French Polio and Landry's ascending paralysis).6. The method of claim 1 , wherein the level of gelsolin is in a ...

Papillomavirus pseudoviruses for detection and therapy of tumors

Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP)

Cyanine compounds

Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.

CANCER IMAGING WITH THERAPY: THERANOSTICS

Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided. 1. A method of imaging tumors or cancerous cells or tissue in a subject , comprising the steps ofadministering to said subject a nucleic acid construct comprisingan imaging reporter gene operably linked to a cancer specific or cancer selective promoter;administering to said subject an imaging agent that is complementary to said imaging reporter gene; andimaging tumors or cancerous tissues or cells in said subject by detecting a detectable signal from said imaging agent.2. The method of claim 1 , wherein said imaging reporter gene is selected from the group consisting of luciferase and herpes simplex virus I thymidine kinase (HSV1-tk).3. The method of claim 1 , wherein said imaging reporter gene is HSV1-tk and said subject is a cancer patient.4. The method of claim 1 , wherein said imaging agent is a radiolabeled nucleoside analog.5. The method of claim 4 , wherein said radiolabeled nucleoside analog is 2′-fluoro-2′deoxy-β-D-5-[I]iodouracil-arabinofuranoside claim 4 ,6. The method of claim 1 , wherein said step of imaging is carried out via single photon emission computed tomography (SPECT) or by positron emission tomography (PET)7. The method of claim 1 , wherein said imaging reporter gene is luciferase and said subject is a laboratory animal.8. The method of claim 7 , wherein said imaging agent is a luciferase substrate.9. The method of claim 1 , wherein said nucleic acid construct is present in a polyplex with a cationic polymer.10. The method ...

Liquid preparation for oral administration used for ct colonography and composition for gastrointestinal radiography

The present invention provides a liquid preparation for oral administration that is capable of reducing the amount of colonic irrigation solution taken during gastrointestinal pretreatment and decreasing the burden on the subject without sacrificing test accuracy and without prolonging the time required for pretreatment, and a composition for gastrointestinal radiography used to prepare the liquid preparation for oral administration. Namely, provided are a liquid preparation for oral administration taken during gastrointestinal imaging by CT colonography that comprises an iodine compound and a water-soluble polymer or saline laxative, wherein 300 mL to 1200 mL are taken on the day before CT colonography in a single administration or divided among several administrations, and a composition for gastrointestinal radiography comprising an iodine compound and a water-soluble polymer or saline laxative, wherein 300 mL to 1200 mL are taken in the form of an aqueous solution, having an iodine content of 3.5 mg/mL to 90 mg/mL prepared by dissolving in water, on the day before CT colonography in a single administration or divided among several administrations.

Radiopaque Embolic Particles

A radiopaque particulate material one or more of SiO 2 , TiO 2 , La 2 O 3 , Na 2 O and MgO and useful for embolization which optionally includes therapeutic components that are released in vivo.

EMBOLIC DEVICES

Described herein are apparatus, compositions, systems and methods for occluding vascular structures and vascular malformations with radiopaque hydrogel filaments. The filaments can contain no support members and can be CT and MR compatible. Methods of forming such filaments are also disclosed. 1. An hydrogel for implantation comprising:a shapeable polymeric filament formed from a combination of precursors comprising trimethylolpropane ethoxylate triacrylamide; at least one ethylenically unsaturated acrylamide monomer and at least one ethylenically unsaturated methacrylate monomer; and a crosslinker; and comprising at least one visualization agent; andwherein the hydrogel includes no metal support members.2. The hydrogel according to claim 1 , having reduced beam hardening artifacts when imaged using computed tomography.3. The hydrogel according to claim 1 , wherein the at least one visualization agent is selected from metallic powders claim 1 , gadolinium claim 1 , superparamagnetic iron oxide particles claim 1 , barium sulfate or a combination thereof.4. The hydrogel according to claim 1 , wherein the polymeric filament has a diameter of less than about 0.03 inches.5. The hydrogel according to claim 1 , wherein the polymeric filament is substantially non-resorbable.6. The hydrogel according to claim 1 , wherein the polymeric filament is biodegradable.7. The hydrogel according to claim 1 , wherein the at least one ethylenically unsaturated acrylamide monomer is t-butyl acrylamide.8. The hydrogel according to claim 1 , wherein the at least one ethylenically unsaturated methacrylate monomer is hydroxyethyl methacrylate.9. The hydrogel according to claim 1 , wherein the ethylenically unsaturated acrylamide monomer and ethylenically unsaturated methacrylate monomer are a combination of hydroxyethyl methacrylate and t-butyl acrylamide.10. The hydrogel according to claim 1 , wherein the difunctional claim 1 , shapeable macromer is trimethylolpropane ethoxylate ...

Opacity technology

A catheter device comprising a chamber containing an opacity enhancing substance is disclosed. The opacity enhancing substance is in a dried or semi-dried form within the chamber of the device. Release of a liquid into the chamber suspends the substance and forms an opacity enhancing solution that is released into the lumen of the device in order to enhance the opacity of the device for imaging.

STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS

The invention encompasses compositions containing an iodinated contrast agent and a substituted cyclodextrin wherein the cyclodextrin stabilizes the contrast agent against degradation by ultraviolet or visible light exposure. 2. The composition of claim 1 , wherein the composition is heat sterilized prior to exposure to the UV light.3. The composition of claim 2 , wherein the heat sterilization comprises steam sterilization.4. The composition of claim 3 , wherein the steam sterilization occurs at 115-116° C. for at least 30 minutes claim 3 , 121-123° C. for at least 15 minutes claim 3 , 126-129° C. for at least 10 minutes claim 3 , or 134-138° C. for at least 3 minutes.5. The composition of claim 1 , wherein the pharmaceutically acceptable buffering agent is selected from the group consisting of tromethamine claim 1 , phosphate claim 1 , and meglumine claim 1 , and their pharmaceutically acceptable salts.6. The composition of claim 1 , wherein the pH of the composition is 6.5 to 7.7.7. The composition of claim 1 , wherein the pH of the composition is 7.4.8. The composition of claim 1 , wherein the contrast agent:substituted cyclodextrin mole ratio is from 1:0.02 to 1:2.9. The composition of claim 1 , further comprising one or more components selected from the group consisting of pH adjusting agents claim 1 , antioxidants claim 1 , chelating agents and inert gasses.10. The composition of claim 1 , wherein the substituted cyclodextrin is selected from the group consisting of sulfoalkylether cyclodextrins claim 1 , 2-hydroxypropyl cyclodextrins claim 1 , partially methylated cyclodextrins and sulfoalkylether alkylether cyclodextrins.11. The composition of claim 1 , wherein the iodinated contrast agent is selected from the group consisting of iohexyl claim 1 , ioversol claim 1 , diatrizoate meglumine and ioxaglate claim 1 , and the substituted cyclodextrin is selected from the group consisting of sulfoalkylether cyclodextrins claim 1 , partially methylated cyclodextrins ...

Injectable microspheres for dermal augmentation and tissue bulking

The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.

ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR ANTIBODIES FOR DIAGNOSTIC AND CLINICAL APPLICATIONS

The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases. 1. A method of detecting OFA/iLRP in a sample comprising: (a) contacting the sample with a first and a second antibody that specifically bind to a region of OFA/iLRP , wherein at least one of the antibodies is specific for OFA/iLRP; (b) allowing the antibodies to bind to OFA/iLRP and form a sandwich with OFA/iLRP; and (c) detecting the expression of OFA/iLR in the sample using the antibody specific for OFA/iLRP.2. A method in accordance with claim 1 , wherein one of the antibodies binds to both OFA/iLRP and mature LRP.3. A method of claim 2 , wherein the antibody recognize both OFA/iLRP and mature LRP acts as a capture antibody claim 2 , and the antibody specific for OFA/iLRP acts as a detection antibody.4. A method of claim 1 , wherein the first antibody is 3G7 claim 1 , and the second antibody is 2C6.5. A method of detecting cancer in a sample comprising: (a) contacting the sample with antibodies specific for OFA/iLRP; (b) contacting the sample with a biotinylated secondary antibody; and (c) detecting OFA/iLRP in the sample using streptavidin claim 1 , wherein the detection of OFA/iLRP in the sample is indicative of cancer.6. A method of determining the amount of OFA/iLRP in a sample comprising: (a) conjugating an antibody specific for OFA/iLRP to a fluorophore; (b) contacting the conjugated antibody with sample; and (c) determining the amount of OFA/iLRP in the sample using fluorescent polarization.7. A method of determining the amount of OFA/iLRP positive cancer cells in a blood sample comprising: (a) contacting a blood ...

CO-CRYSTALS AND SALTS OF CONTRAST AGENTS AND IMAGING

The invention provides co-crystals and salts of contrast agents as well as methods to use and prepare the co-crystals and salts. 1. A co-crystal or salt comprising:a) a contrast agent; andb) a co-crystal former comprising one or more N-aryl groups.2. The co-crystal of .3. The salt of .4. The co-crystal or salt of claim 1 , wherein the contrast agent is a computed tomography contrast agent.5. The co-crystal or salt of claim 1 , wherein the contrast agent is an iodinated contrast agent.6. The co-crystal or salt of claim 5 , wherein the iodinated contrast agent includes one or more covalently bonded iodos wherein the iodinated contrast agent has a molecular mass of less than 750 AMU.7. The co-crystal or salt of claim 5 , wherein the iodinated contrast agent is phenyl or pyridin-4(1H)-one claim 5 , wherein the phenyl or pyridin-4(1H)-one is substituted with one or more iodos and one or more groups selected from —COH claim 5 , —NHC(═O)CH claim 5 , —N(CH)C(═O)CH claim 5 , —CHNHC(═O)CH claim 5 , —CHCH(OH)CHOH claim 5 , —NHand —CHCH(CHCH)COH.8. The co-crystal or salt of claim 1 , wherein the contrast agent is diatrizoic acid (DTA) claim 1 , metrizoic acid claim 1 , iodamide claim 1 , iopydol claim 1 , acetrizoic acid (ATA) or iopanoic acid (IPA).9. The co-crystal or salt of claim 1 , wherein the contrast agent is diatrizoic acid (DTA) claim 1 , acetrizoic acid (ATA) or iopanoic acid (IPA).10. The co-crystal or salt of claim 1 , wherein the co-crystal former has a molecular mass of less than 500 AMU.11. The co-crystal or salt of claim 1 , wherein the co-crystal former includes one or more groups selected from pyridyl claim 1 , phenazinyl and acridinyl.12. The co-crystal or salt of claim 1 , wherein the co-crystal former is pyridyl claim 1 , phenazinyl or acridinyl claim 1 , wherein the pyridyl claim 1 , phenazinyl or acridinyl are optionally substituted with one or more halo claim 1 , —NHor —(C-C)alkenylpyridyl.13. The co-crystal or salt of claim 1 , wherein the co-crystal ...

Method for generating a contrast medium-assisted x-ray image and x-ray system

A method is disclosed for generating at least one x-ray image of a patient having incorporated contrast medium, using x-rays having an energy spectrum and an x-ray detector. The energy spectrum is modified by at least one first filter arranged in the beam path in front of the patient, the patient absorbing a dose in order to generate detector data for the x-ray image and the x-ray image having a CNR value which represents the ratio of the maximum contrast in the image to the noise. The energy spectrum and contrast medium are matched to each other, taking into account the thickness of the patient to be x-rayed, in such a way that an optimization criterion which is taken from an x-ray image that is generated or simulated by way of trials is maximized. Furthermore, an x-ray system is also disclosed.

Multi-encapsulated formulations made with oxidized cellulose

A microsphere and method for forming the same are disclosed. The microsphere includes modified cellulose and at least one of a visualization agent, a magnetic material, or a radioactive material.

Administration of Growth Factors for the Treatment of CNS Disorders

A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and/or dysfunction is described.

PRUSSIAN BLUE BASED NANOPARTICLE AS MULTIMODAL IMAGING CONTRAST MATERIAL

The invention relates to a Prussian Blue based nanoparticle comprising a Prussian Blue based metal core doped with one or more metal isotope and an organic biocompatible coating. The invention relates furthermore to a process for the preparation of said nanoparticle, and the use thereof as imaging contrast material or in the therapy. 1. A Prussian Blue based nanoparticle comprising a Prussian Blue based metal core doped with one or more metal isotope and an organic biocompatible coating.2. A Prussian Blue based nanoparticle according to claim 1 , wherein said metal core comprises Prussian Blue or one or more Prussian Blue analogue of the formula{'br': None, 'sub': x', 'm', '6', 'n, 'AM′[M(CN)]'}whereinA denotes a metal selected from the group consisting of Li, Na, K, Rb, Cs, Fr and Tl,M denotes a metal selected from the group consisting of V, Cr, Mn, Fe, Co, Ni, Cu, Ga, Zr, Nb, Mo, Ru, Cd, In, Hf, Ta, W, Os and Hg,M′ denotes a metal selected from the group consisting of Ca, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Sr, Zr, Nb, Mo, Ru, Rh, Pd, Ag, Cd, In, Lu, Ba, Hf, Ta, W, Os, Pt, Hg, La, Eu, Gd, Tb, Dy and Ho,m denotes 0 to 5,x denotes 0 to 5, andn denotes 0.5 to 10.3. A Prussian Blue based nanoparticle according to claim 1 , wherein said metal isotope is selected from the group consisting of Li claim 1 , Na claim 1 , K claim 1 , Rb claim 1 , Cs claim 1 , Fr claim 1 , Ga claim 1 , In claim 1 , Tl claim 1 , Ca claim 1 , Sc claim 1 , V claim 1 , Cr claim 1 , Mn claim 1 , Fe claim 1 , Co claim 1 , Ni claim 1 , Cu claim 1 , Zn claim 1 , Sr claim 1 , Y claim 1 , Zr claim 1 , Nb claim 1 , Mo claim 1 , Ru claim 1 , Rh claim 1 , Pd claim 1 , Ag claim 1 , Ba claim 1 , La claim 1 , Stn claim 1 , Eu claim 1 , Gd claim 1 , Tb claim 1 , Dy claim 1 , Ho claim 1 , Lu claim 1 , Hf claim 1 , Ta claim 1 , W claim 1 , Re claim 1 , Os claim 1 , Ir claim 1 , Pt claim 1 , Au claim 1 , Hg claim 1 , Pb and Bi.4. A Prussian Blue based nanoparticle according to claim 1 , wherein said biocompatible ...

CUPREDOXIN DERIVED TRANSPORT AGENTS AND METHODS OF USE THEREOF

The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer. 1. A peptide , consisting of a sequence that has at least about 90% amino acid sequence identity to less than a full-length wild-type cupredoxin or H.8 outer membrane protein , and which facilitates the entry of a linked molecule into a mammalian cancer cell.2. The peptide of claim 1 , wherein the cupredoxin is selected from the group consisting of azurin claim 1 , plastocyanin claim 1 , rusticyanin claim 1 , pseudoazurin claim 1 , auracyanin and azurin-like protein.3Pseudomonas aeruginosa, Phormidium laminosum, Thiobacillus ferrooxidans, Achromobacter cycloclastes, Pseudomonas syringa, Neisseria meningitidis, Vibrio parahaemolyticus, Bordetella bronchiseptica, Bordetella pertussis, Chloroflexus aurantiacusNeisseria gonorrhoeae.. The peptide of claim 1 , wherein the peptide is derived from a organism selected from the group consisting of and4. The peptide of claim 1 , wherein the cupredoxin is selected from the group consisting of SEQ ID NO: 1 claim 1 , SEQ ID NO: 2 claim 1 , SEQ ID NO: 3 claim 1 , SEQ ID NO:4 claim 1 , SEQ ID NO: 29 claim 1 , SEQ ID NO: 30 claim 1 , SEQ ID NO: 31 claim 1 , SEQ ID NO: 32 claim 1 , SEQ ID NO: 33 claim 1 , SEQ ID NO: 34 claim 1 , SEQ ID NO: 36 and SEQ ID NO: 43.5. The peptide of claim 1 , which is at least about 10 residues and not more than about 50 residues in length.6. The peptide of claim 1 , comprising a sequence which has at least about 90% amino acid sequence identity to a sequence selected from the group consisting of SEQ ID NO: 5 claim 1 , SEQ ID NO: 6 claim 1 , SEQ ID NO: 7 claim 1 , SEQ ID NO: 9 claim 1 , SEQ ID NO: 37 claim 1 , SEQ ID NO: 38 claim 1 , SEQ ID NO: 39 claim 1 , SEQ ID NO: 40 claim 1 , SEQ ID NO: 41 claim 1 , ...

Silica nanoparticle for diagnostic imaging, method for producing the same, and biosubstance labeling agent

A silica nanoparticle for diagnostic imaging that may be capable of use for X-ray CT, fluorescent imaging, or the like, and have high emission intensity. A method for producing such a silica nanoparticle for diagnostic imaging is provided. Also, a biosubstance labeling agent using the silica nanoparticle for diagnostic imaging is provided. The silica nanoparticle for diagnostic imaging encapsulates an organic fluorescent dye and a metal complex, wherein a ligand of the metal complex form a covalent bond with constituent molecules of the silica nanoparticle.

Use of radiographic contrast agents for detecting dental caries

The present invention provides methods of imaging dental tissue. More particularly, the invention relates to a method of imaging dental caries by administering a topical intra-oral composition that provides enhanced radiographic imaging.

Implants and biodegradable fiducial markers

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking. Applications include a method of treating a patient with a pharmaceutically acceptable implant system comprising implanting a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles, wherein the collection comprises a plurality of sets of the particles, with the sets having different rates of biodegradation.

TRANSPORT AGENTS FOR CROSSING THE BLOOD-BRAIN AND INTO BRAIN CANCER CELLS AND METHODS OF USE THEREOF

The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer. 1Neisseria. An isolated transit peptide which is a variant , derivative or structural equivalent of Laz , Lip or Pan 1 from , and which facilitates the entry of a linked molecule into a mammalian brain cancer cell or across the blood-brain barrier.2. The transit peptide of claim 1 , to which the H.8 region of Laz (SEQ ID NO: 24) has at least 90% amino acid identity.3. The transit peptide of claim 1 , wherein the peptide is SEQ ID NO: 24.4. The transit peptide of claim 1 , wherein the transit peptide is modified to extend or optimize the half life of the peptide in the bloodstream.5. A transit peptide comprising a region consisting of at least 4 imperfect or perfect repeats of Ala-Ala-Glu-Ala-Pro (SEQ ID NO: 25) claim 1 , and which has at least about 50% AAEAP (SEQ ID NO: 25) pentapeptide repeats per total length.6. A transit peptide of claim 5 , wherein the region of repeats is at least about 90% identical to a peptide comprising an equal number of repeats of Ala-Ala-Glu-Ala-Pro (SEQ ID NO: 25).7. The transit peptide of claim 5 , which is synthetic.8. The transit peptide of claim 5 , wherein the transit peptide is modified to extend or optimize the half life of the peptide in the bloodstream.9. A complex comprising at least one cargo compound and a transit peptide claim 5 , wherein the transit peptide is the peptide of and the transit peptide is linked to the ...

METHOD OF TRACKING GROWTH AND METASTASIS OF SPECIFIC CELLS IN VIVO

A method of tracking growth and metastasis of specific cells in vivo is disclosed. The method of the disclosure includes culturing the specific cells in a medium containing 0.1 μM to 10 mM nanoparticles as a biomarker for X-rays, such that the specific cells carry the nanoparticles, administering the specific cells carrying the nanoparticles to a subject, irradiating the subject by an X-ray source, and determining the growth and metastasis of the specific cells by X-ray images of the nanoparticles in the subject. 1. A method of tracking growth and metastasis of specific cells in vivo , comprising:culturing the specific cells in a medium containing about 0.1 μM to 10 mM of nanoparticles as a biomarker for X-rays, such that the specific cells carry the nanoparticles;administering the specific cells carrying the nanoparticles to a subject;irradiating the subject by an X-ray source; anddetermining the growth and metastasis of the specific cells by X-ray images of the nanoparticles in the subject.2. The method of tracking growth and metastasis of specific cells in vivo as claimed in claim 1 , wherein the X-ray source comprises a synchrotron radiation X-ray source claim 1 , a medical X-ray source claim 1 , or a laboratory X-ray source.3. The method of tracking growth and metastasis of specific cells in vivo as claimed in claim 1 , wherein the X-ray source has a dose of less than about 100 Gy.4. The method of tracking growth and metastasis of specific cells in vivo as claimed in claim 1 , wherein the dose of the X-ray source is between about 1 Gy and 30 Gy.5. The method of tracking growth and metastasis of specific cells in vivo as claimed in claim 1 , wherein the irradiation is performed for less than 30 minutes.6. The method of tracking growth and metastasis of specific cells in vivo as claimed in claim 1 , wherein the irradiation is performed for between about 100 milliseconds and 5 minutes.7. The method of tracking growth and metastasis of specific cells in vivo as ...

CONTAINER WITH CONCENTRATED SUBSTANCE AND METHOD OF USING THE SAME

Apparatus and methods are described herein for a container with a unit dose of a concentrated substance that can be diluted and orally consumed using the container. In some embodiments, an apparatus includes a container body that defines an opening in fluid communication with an interior of the container body. A cap is coupled to the container body and encloses the opening. A unit dose of a concentrated medicament or a concentrated contrast agent is disposed within the interior of the container body. The unit dose of concentrated medicament or contrast agent can be diluted to a select dilution strength with a volume of a liquid receivable through the opening and within the interior of the container body. In some embodiments, the apparatus can include a barrier member in which the container body and cap can be disposed to protect the medicament or contrast agent from light and/or moisture. 1. A method , comprising:removing from an interior of a barrier member a container including a container body and a cap coupled to the container body, the container body having a unit dose of an excipient free concentrated contrast agent in powder form disposed within an interior of the container body, the barrier member configured to shield the unit dose of excipient free concentrated contrast agent from at least one of light or moisture;removing the cap from the container body;after the removing, adding a volume of a liquid to the interior of the container body such that the unit dose of the excipient free concentrated contrast agent is diluted to a select dilution strength; andafter the adding, providing the container body to a patient to orally consume the diluted excipient free concentrated contrast agent.2. The method of claim 1 , wherein the container body is provided to the patient prior to an imaging procedure to be performed on the patient.3. The method of claim 1 , further comprising:after the adding the volume of liquid, coupling the cap to the container body; ...

POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS

The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline. 1. A coating comprising:a tetrafluoroethylene copolymer mixed with a water soluble agent,wherein the coating has at least a 50% reduction in excess heat capacity on a tetrafluoroethylene copolymer mass basis as compared with a coating of tetrafluoroethylene copolymer with no water soluble agent.2. The coating of claim 1 , wherein the coating has at least an 80% reduction in excess heat capacity on a tetrafluoroethylene copolymer mass basis as compared with a coating of tetrafluoroethylene copolymer with no water soluble agent.3. The coating of claim 1 , wherein said tetrafluoroethylene copolymer comprises a functional group selected from a group consisting of acetate claim 1 , alcohol claim 1 , amine claim 1 , and amide.4. The coating of claim 1 , wherein said tetrafluoroethylene copolymer is poly(tetrafluoroethylene-co-vinyl acetate) (TFE-VAc).5. The coating of claim 1 , wherein said tetrafluoroethylene copolymer is poly(tetrafluoroethylene-co-vinyl alcohol) (TFE-VOH).6. The coating of claim 1 , wherein said tetrafluoroethylene copolymer is poly(tetrafluoroethylene-co-vinyl alcohol-co-vinyl[aminobutyraldehyde acetal(TFE-VOH-AcAm).7. The coating of 1 claim 1 , wherein said water soluble agent is a therapeutic agent.9. A coating comprising:a tetrafluoroethylene copolymer mixed with a water soluble agent,wherein the coating is phase mixed as measured by modulated differential scanning calorimetry.10. The coating of claim 9 , wherein the coating has at least a 50% reduction in excess heat capacity on a tetrafluoroethylene copolymer mass basis as ...

ENERGY MODULATED LUMINESCENCE TOMOGRAPHY

The present approach generally relates to systems and methods for implementing energy modulated tomographic imaging of nanoparticles. In certain embodiments, a first energy is used to activate probe particles labeling an anatomy or tissue of interest. The probe particles, once activated, emit photons at a different rate and/or spectrum in response to an underlying physiological event, such as action potentials propagating in the labeled anatomy or tissue. The emitted photons may then be detected and used to map or image the occurrence of the physiological event. 1. A neural activity monitoring system , comprising:an energy delivery mechanism configured to deliver an activation energy to a measurement volume when a set of nanoparticles are present within the measurement volume, wherein the nanoparticles emit photons when activated by the external energy source and, once in an activated state, further emit a pulse of photons in response to a physiological event when such a physiological event occurs within the measurement volume.one of more photodetectors configured to detect photons emitted by the nanoparticles in response to the physiological event;a data acquisition system configured to read out signals generated by the one or more photodetectors in response to the detected photons; andan image reconstructor or a signal analyzer, and event recorder configured to reconstruct one or more images and/or features of a nanoparticle distribution, time domain activity, and temporal relationship among measured signals and biological events derived from these measurements and energy excitation parameters.2. The system of claim 1 , wherein the temporal relationship among measured signals and biological features corresponds to functional map of neuronal communication.3. The system of claim 1 , wherein the energy delivery mechanism comprises an X-ray source.4. The system of claim 1 , wherein the energy delivery mechanism further comprises a focusing element comprising one or ...

BIO-COMPATIBLE RADIOPAQUE DENTAL FILLERS FOR IMAGING

Dental contrast formulations (“fillers”) of tailorable X-Ray radiopacity and methods for their use are provided. The disclosed fillers include mixtures of solid particles suspended in a biocompatible fluid. The solid particles contain one or more X-ray radiopaque materials. The biocompatible fluid can also contain one or more soluble X-ray radiopaque components. By controlling the composition of the solid particles, the composition of the biocompatible fluid, and the loading of the solid particles in the biocompatible fluid, the X-ray radiopacity and stability of the filler can be tailored to allow for improved discrimination of the filler within periodontal pockets, relative to adjacent soft tissue and teeth, so that the 3-D shape, volume, and depth of the pocket can be precisely and rapidly determined by X-Ray imaging. 1. A dental contrast composition comprising CaWOparticles dispersed in glycerol.2. The dental contrast composition of claim 1 , wherein the composition comprises 40 wt % suspension of CaWO.3. A composition claim 1 , comprising:particles comprising nanocellulose or diatom silica microshells coated with calcium phosphate suspended in a biocompatible fluid.4. The composition of claim 1 , wherein the calcium phosphate comprises hydroxyapatite.5. The composition of claim 3 , wherein the particles comprise microparticles claim 3 , nanoparticles claim 3 , or a combination thereof.6. The composition of claim 3 , wherein the composition is bioresorbable.7. The composition of claim 3 , wherein the particles have an X-ray radiopacity less than that of teeth or bone and greater than that of soft tissue.8. A contrast agent claim 3 , comprising:{'claim-ref': {'@idref': 'CLM-00003', 'claim 3'}, 'the composition of .'}9. The composition of claim 3 , wherein the microparticles are hollow.10. The composition of claim 3 , wherein the calcium phosphate comprises CaPO.11. The composition of claim 3 , wherein the calcium phosphate comprises Ca(PO)(OH).12. The composition ...

Bismuth-Gadolinium Nanoparticles

Provided herein are nanoparticle compositions (e.g., nanoparticle compositions comprising high atomic number ions) that are useful for imaging diseases in a subject as well as radiosensitizing a disease in a subject (e.g., radiosensitizing a cancer in the subject). Methods of imaging a subject, methods of treating cancer, and processes of preparing the nanoparticle compositions are also provided. 1. A composition , comprising:a nanoparticle core comprising one or more first linking groups covalently bonded to a first ligand and one or more second linking groups covalently bonded to a second ligand;{'sup': 3+', '3+, 'wherein one or more of the first ligands are complexed to Gd ions and one or more of the second ligands are complexed to Bi ions.'}2. The composition of claim 1 , wherein the nanoparticle core is a silica core.3. The composition of claim 1 , wherein the nanoparticle core is a polysiloxane core.4. The composition of any one of to claim 1 , wherein the one or more first linking groups each comprise a Calkylamine covalently bonded to the first ligand.5. The composition of any one of to claim 1 , wherein each of the first ligands is independently selected from the group consisting of 1 claim 1 ,4 claim 1 ,7-triazacyclononanetriacetic acid (NOTA) claim 1 , 1 claim 1 ,4 claim 1 ,7 claim 1 ,10-tetraazacyclododecane-1 claim 1 ,4 claim 1 ,7 claim 1 ,10-tetraacetic acid (DOTA) claim 1 , 1 claim 1 ,4 claim 1 ,7-triazacyclononane-1-glutaric acid-4 claim 1 ,7-diacetic acid (NODAGA) claim 1 , ethylene diamine tetra-acetic acid (EDTA) claim 1 , diethylene triaminepentaacetic acid (DTPA) claim 1 , cyclohexyl-1 claim 1 ,2-diaminetetraacetic acid (CDTA) claim 1 , ethyleneglycol-O claim 1 ,O′-bis(2-aminoethyl)-N claim 1 ,N claim 1 ,N′ claim 1 ,N′-tetraacetic acid (EGTA) claim 1 , N claim 1 ,N-bis(hydroxybenzyl)-ethylenediamine-N claim 1 ,N′-diacetic acid (MED) claim 1 , triethylene tetramine hexaacetic acid (TTHA) claim 1 , hydroxyethyidiamine triacetic acid (HEDTA) claim ...

PER-ORAL NEGATIVE CONTRAST AGENT FOR ABDOMINAL CT

An edible negative contrast agent for CT imaging of the gastrointestinal tract intended for oral intake. The contrast agent is a fluid, aqueous foam displaying a CT density contrast value in the range −300 to −800 HU and having a consistency of 7 to 12 cm as measured with Bostwick consistometer. The contrast agent comprises an aqueous continuous liquid phase having a pH of 6.5 to 8.0 and gas bubbles dispersed in the continuous aqueous liquid phase. The aqueous continuous liquid phase comprises a surfactant, the surfactant being a protein, a hydrocolloid acting as foam stabilizer, a buffering agent, and water. 1. An edible negative contrast agent for CT imaging of the gastrointestinal tract intended for oral intake , the contrast agent being a fluid , aqueous foam displaying a CT density contrast value in the range −300 to −800 HU , wherein the contrast agent comprises an aqueous continuous liquid phase having a pH of 6.5 to 8.0 , the aqueous continuous liquid phase comprising:a surfactant, the surfactant being a protein;a hydrocolloid acting as foam stabilizer;a buffering agent; andwater;and gas bubbles dispersed in the continuous aqueous liquid phase, the contrast agent having a consistency of 7 to 12 cm as measured with Bostwick consistometer over 30 seconds at 23±1° C.2. The edible negative contrast agent according to claim 1 , wherein the gas bubbles dispersed in the continuous aqueous liquid phase are air bubbles.3. The edible negative contrast agent according to or claim 1 , wherein the surfactant comprises ovalbumin.4. The edible negative contrast agent according to any one of the to claim 1 , wherein the contrast agent comprises at least 35 vol % dispersed air bubbles claim 1 , such as more than 50 vol % dispersed air bubbles.5. The edible negative contrast agent according to any one of the to claim 1 , wherein the contrast agent comprises 30 to 70 vol % dispersed air bubbles at 25° C. claim 1 , such as between 35 and 55 vol % dispersed air bubbles at 25° C. ...

SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION

Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue. In other embodiments, the hydrogel polymer is delivered into a joint space to treat joint disease or navicular disease. 115-. (canceled)16. A would healing solid polyglycol-based , fully synthetic , pre-formulation , comprising: (a) at least one solid first compound comprising more than two nucleophilic groups; (b) at least one solid second compound comprising more than two electrophilic groups; (c) optionally , a solid buffer component; (d) optionally , a therapeutic agent; and (e) optionally , a solid viscosity enhancer ,wherein the solid polyglycol-based, fully synthetic, pre-formulation polymerizes and/or gels at a target site of the wound to form a polyglycol-based, fully synthetic, biocompatible hydrogel polymer after addition of a liquid component,wherein the liquid component does not contain any first compound or second compound, and provided that the solid polyglycol-based, fully synthetic, pre-formulation does not contain any aqueous component.17. The wound healing solid polyglycol-based , fully synthetic , pre-formulation , wherein the therapeutic is a solid therapeutic agent.18. The wound healing solid polyglycol-based , fully synthetic , pre-formulation , wherein the liquid component comprises water , saline , a buffer , a therapeutic agent , or a combination thereof.19. The wound healing solid polyglycol-based , fully synthetic , pre-formulation , wherein the solid first compound is a MULTIARM (5k-50k) polyol derivative comprising polyglycol subunits and more than two nucleophilic groups , and wherein the solid second compound is a MULTIARM (5k-50k) polyol derivative ...

POLYPHOSPHAZENE DELIVERY SYSTEM FOR INORGANIC NANOCRYSTALS

Nanoclusters comprising inorganic nanocrystals and a biodegradable polymer are disclosed. The inorganic nanocrystals have a mean particle size of 1 to 500 nm. The inorganic nanocrystals are contained within a core of the nanoclusters, on the surface of the nanoclusters, contained within a core of the nanoclusters, dispersed throughout the nanoclusters, or a combination thereof. The biodegradable polymer allows the inorganic nanocrystals to be excreted renally over a period of time. The nanoclusters can be used for medical imaging or other biomedical applications. 1. A nanocluster comprising:a plurality of inorganic nanocrystals;a biodegradable polymer;wherein the plurality of inorganic nanocrystals are contained on a surface of the nanocluster, within a core of the nanocluster, dispersed throughout the nanocluster, or a combination thereof.2. The nanocluster according to claim 1 , wherein the inorganic nanocrystals are selected from metal nanoparticles claim 1 , nanophosphors claim 1 , MRI imaging agents claim 1 , and quantum dots.3. The nanocluster according to claim 1 , wherein the inorganic nanocrystals comprise nanoparticles selected from the group consisting of gold claim 1 , silver claim 1 , iodine claim 1 , bismuth claim 1 , yttrium claim 1 , ytterbium claim 1 , tantalum claim 1 , tungsten claim 1 , and platinum claim 1 , and alloys claim 1 , combinations claim 1 , compounds claim 1 , and salts thereof.4. The nanocluster according to claim 3 , wherein the inorganic nanocrystals comprise gold nanoparticles.5. The nanocluster according to claim 1 , wherein the inorganic nanocrystals comprise an alloy of silver and gold.6. The nanocluster according to claim 1 , wherein the inorganic nanocrystals comprise doped or undoped iron oxide nanoparticles.7. The nanocluster according to claim 1 , wherein the polymer is a polyphosphazene.8. The nanocluster according to claim 7 , wherein the polyphosphazene is selected from the group consisting of poly(bis(4-carboxyphenoxy) ...

POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS

The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline. 1. A method of preparing a water in solvent emulsion comprising the steps of:a. Dissolving a tetrafluoroethylene copolymer in a water miscible organic solvent;b. Providing a water phase;c. Dissolving an agent comprising one of a water soluble agent and a hydrophobic agent; andd. Combining the tetrafluoroethylene copolymer with the dissolved agent, such that the emulsion is kinetically stable.2. The method of claim 1 , wherein the agent is a therapeutic agent.3. The method of claim 1 , wherein the agent is an inclusion complex comprising a hydrophobic agent and a hydrophilic complexing agent.4. The method of claim 1 , wherein the agent is a water soluble agent which is dissolved into the water phase.5. A method of coating a substrate comprising a water-in-solvent emulsion claim 1 , the method comprising the steps of:a. Providing a water in solvent emulsion comprising a tetrafluoroethylene copolymer, a solvent phase comprising a water miscible organic solvent, an agent comprising one of a water soluble agent and a hydrophobic agent, a water phase, wherein the emulsion is kinetically stable;b. Applying the water-in-solvent emulsion to the substrate; andc. Removing the solvent and water.6. The method of claim 5 , wherein the agent is an inclusion complex comprising a hydrophobic agent and a hydrophilic complexing agent.7. The method of claim 5 , wherein the water phase is less than about 500 nm by Raman spectroscopy.8. The method of claim 5 , wherein the tetrafluoroethylene copolymer comprises functional groups selected from a group consisting of ...

Drug design for application-dependent payload, controlled pharmacokinetic distribution, and renal clearance

Design and use of an administered drug in the form of a nanoparticle or molecule is described. In certain examples, the nanoparticle has a core and a shell surrounding the core. The core may be configured or designed to provide useful X-ray attenuating properties, gamma ray emission properties, magnetic properties, or therapeutic effects. In certain aspects, the nanoparticle or molecule is sized so as to either distribute from or remain in the blood pool, while still being eliminated by the kidneys.

DRUG DESIGN FOR APPLICATION-DEPENDENT PAYLOAD, CONTROLLED PHARMACOKINETIC DISTRIBUTION, AND RENAL CLEARANCE

Design and use of an administered drug in the form of a nanoparticle or molecule is described. In certain examples, the nanoparticle has a core and a shell surrounding the core. The core may be configured or designed to provide useful X-ray attenuating properties, gamma ray emission properties, magnetic properties, or therapeutic effects. In certain aspects, the nanoparticle or molecule is sized so as to either distribute from or remain in the blood pool, while still being eliminated by the kidneys. 1. An agent that can be injected into a subject , wherein the agent comprises:nanoparticles or molecules sized to effect a specific degree of distribution or lack of distribution between tissues, organs, or bodily compartments of the subject while still being eliminated by the kidneyswherein the agent is injected into the veins or arteries and the agent comprises nanoparticles or molecules that either have a size range minimum larger than about 3-4 nm and a size range maximum smaller than about 5-6 nm so as to remain in the blood pool during imaging or have a size range maximum selected to be smaller than about 3-4 nm so as to distribute from the blood pool during imaging.2. The agents of claim 1 , wherein the agent comprises nanoparticles comprising:a core; anda shell surrounding the core.3. The agent of claim 1 , wherein the nanoparticles or molecules contain one or more of X-ray attenuating elements.4. The agent of claim 3 , wherein the one or more X-ray attenuating elements comprise elements that have an atomic number from 53 to 83.5. The agent of claim 1 , wherein the agent is injected into the veins or arteries and the agent comprises nanoparticles or molecules that have a size range maximum selected to be smaller than about 3-4 nm so as to distribute from the blood pool during imaging.6. The agent of claim 1 , wherein the agent is injected into the veins or arteries and the agent comprises nanoparticles or molecules that have a size range maximum selected to be ...

MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS

The present invention provides targeted delivery compositions and methods of using the compositions for treating and diagnosing a disease state in a subject. 173-. (canceled)77. The method of claim 74 , wherein said nanocarrier has embedded in claim 74 , encapsulated in claim 74 , or tethered to a therapeutic agent selected from the group consisting of doxorubicin claim 74 , cisplatin claim 74 , oxaliplatin claim 74 , carboplatin claim 74 , 5-fluorouracil claim 74 , gemcitibine and a taxane.78. The method of claim 74 , wherein said nanocarrier has embedded in claim 74 , encapsulated in claim 74 , or tethered to a diagnostic agent selected from the group consisting of a radioactive agent claim 74 , a fluorescent agent claim 74 , and a contrast agent.82. The method of claim 79 , wherein MMPhas an ICof about 13 nM or lower.83. The method of claim 80 , wherein MMPhas an ICof about 13 nM or lower.84. The method of claim 81 , wherein MMPhas an ICof about 13 nM or lower.85. The method of claim 79 , wherein the administration of the composition inhibits growth of the tumor cells by at least 50%.86. The method of claim 80 , wherein the administration of the composition reduces the tumor burden by at least 50%. The present application claims priority to U.S. Provisional Patent Application No. 61/565,461, filed Nov. 30, 2011, the entirety of which is incorporated herein by reference.NOT APPLICABLENOT APPLICABLECancer is a class of diseases that can affect people of all ages. Accordingly, there is considerable effort to provide therapies that can treat or diagnose cancer in patients. Targeted delivery of nanocarriers in the body has been discussed recently as a potential new avenue in drug delivery and diagnostic imaging techniques. Unfortunately, obstacles still exist in making nanocarrier based-products that can effectively treat or diagnose cancer.Many if not all solid tumors either express matrix metalloproteinase (MMP) enzymes on their surface or excrete it into the ...

Tumorspecific PET/MR(T1), PET/MR(T2) and PET/CT contrast agent

New types of nanoparticle-based dual-modality positron emission tomography/magnetic resonance imaging (PET/MRI) and positron emission tomography/computed tomography (PET/CT) tumorspecific contrast agents have been developed. The base of the new type contrast agents is biopolymer-based nanoparticle with PET, MRI and CT active ligands. The nanoparticle contains at least one polyanion and polycation, which form nanoparticles via ion-ion interaction. The self-assembled polyelectrolytes can transport gold nanoparticles as CT contrast agents, or SPION or Gd(III) ions as MRI active ligands, and are labeled using a complexing agent with gallium as PET radiopharmacon. Furthermore, these dual modality PET/MRI and PET/CT contrast agents are labeled with targeting moieties to realize the tumorspecificity. 1. A targeting PET/MRI or PET/CT tumorspecific nanoparticulate contrast composition comprising (i) at least two , preferably water-soluble , biocompatible and biodegradable nanoparticle polyelectrolyte biopolymers; (ii) a targeting molecule conjugated a polyanion biopolymer; (iii) a complexing agent conjugated to a polycation biopolymer , (iv) an MR or CT active ligand complexed to the nanoparticles , and (v) a radionuclide , preferably gallium complexed to the nanoparticles.2. The targeting contrast composition as claimed in claim 1 , wherein the MR or CT active ligand is a paramagnetic ion claim 1 , preferably a lanthanide or a transition metal ion claim 1 , more preferably a gadolinium- claim 1 , a manganese- or a chromium-ion claim 1 , most preferably a gadolinium ion as T1 MR active ion claim 1 , a superparamagnetic iron oxide nanoparticle (SPION) as T2 MR active ligand claim 1 , or a gold nanoparticle as CT contrast ligand.3. The targeting contrast composition as claimed in claim 1 , whereina) the gadolinium ions are complexed to the nanoparticles via complexing agents conjugated to a polycation biopolymer; orb) the SPION or gold nanoparticles are formed in presence of a ...

PET TRACER FOR IMAGING OF NEUROENDOCRINE TUMORS

There is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq. 2. Compound according to for in vivo diagnosis or imaging claim 1 , for example by PET claim 1 , of a neuroendocrine tumor claim 1 , wherein the compound is to be administered with a target dose in the range of 191-210 MBq.3. Use of a compound according to or a pharmaceutically acceptable salt thereof for the manufacture of a composition for use in a radiographic imaging method claim 1 , wherein cells or tissues are to be contacted with the compound; and a radiographic image is to be made.4. The use of claim 3 , wherein the compound is detected by a gamma camera claim 3 , positron emission tomography (PET) or single photon emission tomography (SPECT) claim 3 , wherein the compound is administered with a target dose in the range of 150-250 MBq claim 3 , preferable in the range of 191-210 MBq.5. Use of a compound according to or a pharmaceutically acceptable salt thereof in the preparation of a composition for detection of a tumor claim 1 , tumor tissue claim 1 , cancer or metastasis in a subject claim 1 , wherein the compound is administered with a target dose in the range of 150-250 MBq claim 1 , preferable in the range of 191-210 MBq.6. Use of a compound of for the manufacture of a radiopharmaceutical for use in a method of in vivo imaging claim 5 , wherein the compound is administered with a target dose in the range of 191-210 MBq.7. Use of a compound according to or a pharmaceutically acceptable salt thereof for the production of a composition suitable in diagnosis or therapy wherein the compound is ...

RADIOPAQUE MONOMERS, POLYMERS, MICROSPHERES, AND METHODS RELATED THERETO

Radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of using the radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of manufacturing radiopaque monomers, polymers, and microspheres are disclosed herein. 120-. (canceled)24. The method of claim 21 , wherein the polymer comprises an anionic functional group.25. The method of claim 21 , wherein the polymer comprises a cationic functional group.26. The method of claim 21 , wherein the polymer is non-resorbable within a body of a patient.27. The method of claim 21 , wherein the polymer is radiopaque.28. The method of claim 21 , wherein the composition comprises microspheres.29. The method of claim 21 , wherein the composition further comprises at least one of a cross-linker claim 21 , a gelatin claim 21 , or a coloring agent.30. The method of claim 21 , wherein the composition further comprises an additional radiopaque agent.31. The method of claim 21 , wherein the composition further comprises a magnetic agent.32. The method of claim 21 , further comprising:detecting a location of the polymer more than about 24 hours, more than about 48 hours, more than about a week, or more than about a month after introduction of the polymer.33. A method of embolization claim 21 , comprising: a polymer comprising a polymerized monomer comprising a polymerizable group; a spacer; an anionic functional group; and an iodine;', 'wherein the polymer is radiopaque., 'injecting an embolic composition into a blood vessel of a patient, the composition comprising35. The method of claim 33 , further comprising:detecting a location of the polymer more than about 24 hours, more than about 48 hours, more than about a week, or more than about a month after introduction of the polymer.36. The method of claim 33 , wherein the polymer is non-resorbable within a body of the patient.37. The method of claim 33 , wherein the composition comprises microspheres.38. A method of embolization claim 33 , ...

IMPLANTATION DEVICES INCLUDING HYDROGEL FILAMENTS

Described are devices for implantation comprising a hydrogel filament wherein the hydrogel filament includes a low molecular weight ethylenically unsaturated macromer, an ethylenically unsaturated monomer, and a visualization agent. Methods of making and using these devices are also described. 1. A device for implantation comprising:a hydrogel filament attached to a coupler wherein the coupler is attached to a pusher,wherein the hydrogel filament includes a low molecular weight ethylenically unsaturated macromer; an ethylenically unsaturated monomer; and a visualization agent,wherein said device contains no support members.2. The device of claim 1 , wherein said macromer has a molecular weight of about 100 grams/mole to about 5000 grams/mole.3. The device of claim 1 , wherein said macromer comprises polyethylene glycol claim 1 , propylene glycol claim 1 , poly(tetramethylene oxide) claim 1 , poly(ethylene glycol) diacrylamide claim 1 , poly(ethylene glycol) diacrylate claim 1 , poly(ethylene glycol) dimethacrylate claim 1 , derivatives thereof claim 1 , or combinations thereof.4. The device of claim 1 , wherein said visualization agent comprises an aromatic ring having a single unsaturation point and at least one iodine atom.5. The device of claim 1 , wherein said visualization agent comprises barium sulfate claim 1 , gadolinium claim 1 , or iron oxide.6. The device of claim 5 , wherein said visualization agent is barium sulfate.7. The device of claim 1 , wherein said ethylenically unsaturated monomer and said visualization agent comprise 2 claim 1 ,4 claim 1 ,6-triiodophenyl penta-4-enoate claim 1 , 5-acrylamido-2 claim 1 ,4 claim 1 ,6-triiodo-n claim 1 ,n′-bis-(2 claim 1 ,3 dihydroxypropyl) isophthalamide claim 1 , derivatives thereof claim 1 , or combinations thereof.8. The device of claim 1 , wherein said macromer and said monomer are crosslinked with N claim 1 ,N claim 1 ,N′ claim 1 ,N′-tetramethylethylenediamine claim 1 , ammonium persulfate claim 1 , ...

IMPLANTABLE PROSTHESIS WITH RADIOPAQUE PARTICLES AND METHOD OF MAKING SAME

An implantable prosthesis can comprise a strut having a lumen, radiopaque particles within the lumen, and a polymer binder. The polymer binder retains the radiopaque particles within the lumen. The strut may have side holes through which a therapeutic agent may pass and through which the radiopaque particles are incapable of passing. The polymer binder may be absent or optional. The radiopaque particles can have sizes that prevent them from escaping out of the lumen through the side holes. The radiopaque particles placed within the lumen can improve visualization of the prosthesis during an implantation procedure. 127-. (canceled)28. A method of making an implantable prosthesis , the method comprising:placing radiopaque particles within a lumen of a strut having a plurality of side holes extending from the lumen to an exterior surface of the strut, the radiopaque particles having sizes that prevent the radiopaque particles from passing through the side holes.29. The method of claim 28 , wherein the placing of the radiopaque particles within the lumen includes introducing the radiopaque particles through an end hole of the strut.30. The method of claim 29 , further comprising crimping claim 29 , sealing or plugging the end hole after the introducing of the radiopaque particles through the end hole.31. The method of claim 29 , further comprising forming the side holes through the strut before the introducing of the radiopaque particles through the end hole.32. The method of claim 29 , further comprising forming the side holes through the strut after the introducing of the radiopaque particles through the end hole.33. The method of claim 32 , wherein forming the side holes is performed by any of drilling the strut claim 32 , chemical etching the strut claim 32 , and milling a metal wall of the strut.34. The method of claim 29 , wherein the end hole has a central axis coaxial with a central axis of the lumen.35. The method of claim 28 , wherein further comprising ...

Compounds And Methods For Selective Imaging And/Or Ablation

The invention relates generally to compounds and methods for imaging and/or selective ablation of nitroreductase-expressing cells and/or biological agents. More particularly, although not exclusively, the invention provides compounds that are selectively metabolised by bacterial nitroreductases and are substantially insensitive to metabolism under oxic or hypoxic conditions by human nitroreductase enzymes. 2. (canceled)3. (canceled)4. The method as claimed in claim 1 , wherein the method comprises a method of immunohistochemical imaging and wherein Y is selected from IIIb claim 1 , IIIc or IIIh and R is selected from CHF or CHF.5. (canceled)921-. (canceled)22. A method of treatment or diagnosis of a disease using the compound of claim 6 , wherein the disease is selected from the group consisting of cancer claim 6 , Parkinson's disease claim 6 , Alzheimer's disease claim 6 , stroke claim 6 , heart disease claim 6 , rheumatological diseases and a disease treated by stem-cell transplantation.2331-. (canceled) The invention relates generally to compounds that have utility in imaging and/or selective ablation of nitroreductase-expressing cells or biological agents. More particularly, although not exclusively, said compounds have use in non-invasive imaging techniques, monitoring of therapeutic cell populations and gene-directed enzyme prodrug therapy.Selective targeting of cancer tissues can be achieved by tumour-tropic organisms, including certain replication competent viral vectors and bacteria. Such organisms are generally antineoplastic in their own right, and a number are in clinical trials (or clinical use) as novel therapeutic agents. Ideally such agents would be introduced via systemic administration, and would “seek out” cancerous tissues. However, applications to date have been limited owing to an inability to non-invasively image the location of viruses or bacteria in the body post-administration. The self-amplifying nature and uncertain tropism for human ...

METHOD FOR MANUFACTURING MARKER WITH AERATED HYDROGEL

A system for aerating a marker material. The system includes a first container, a second container, and an aeration connector. The aeration connector includes a body and a screen disk disposed within the body. The first container is in communication with the second container via the aeration connector. The screen disk of the aeration connector is configured to aerate a marker material as the marker material is repeatedly passed between the first container and the second container. 1. A system for manufacturing aerated hydrogel comprising:a first container for containing hydrogel material;a second container for containing aerating fluid;a coupler positioned between and having a lumen in fluid communication with the first and second containers; anda filter positioned in a fluid communication path between the first and second containers and having a plurality of openings with each opening having a smaller area than the lumen of the coupler.2. The system of claim 1 , further comprising first and second transfer rods that transfer the hydrogel material and the aerating fluid between the first and second containers through the filter and the coupler to mix the hydrogel material and the aerating fluid together to create the aerated hydrogel.3. The system of claim 1 , wherein the highest width of at least one opening of the filter is 1000 microns or less.4. The system of claim 1 , wherein the filter includes a disk having a plurality of round openings with each opening having a diameter of 1000 microns or less.5. The system of claim 1 , wherein the filter includes first and second filters spaced from each other.6. The system of claim 1 , wherein the filter includes first and second filters spaced and circumferentially offset from each other.7. The system of claim 1 , wherein the coupler includes a luer coupler and the filter is positioned inside the luer coupler.8. The system of claim 1 , wherein the coupler includes a luer coupler and the filter includes first and second ...

INTRALIPID-IODINE FOR IMAGING

The present invention relates to intralipid-iodine and intralipid-iodine compounds for use in imaging and therapy. 1. A multidisciplinary and multipotent intralipid-iodine for use in imaging.2. The intralipid-iodine according to claim 1 , wherein said imaging is hysterosalpingography in infertile women.3. The intralipid-iodine according to claim 1 , wherein said imaging is X-ray imaging or cardiac- and limbs-catheterization.4. The intralipid-iodine according to claim 1 , wherein said intralipid-iodine is formulated for injection into the blood stream of a patient.5. The intralipid-iodine according to claim 1 , which is any lipid emulsion.6. The intralipid-iodine according to claim 1 , wherein said intralipid-iodine absorbs/attaches obstructive or potentially-obstructive particles located within blood vessels and/or other organs in the body claim 1 , and removes same to thereby open clogged blood vessels.7. A multidisciplinary and multipotent composition comprising intralipid-iodine for use in imaging.8. The composition according to claim 7 , further comprising a pharmaceutically acceptable carrier adapted for injection.9. The composition according to claim 7 , which is formulated for administration into the blood stream.10. The composition according to claim 7 , wherein said intralipid-iodine is any lipid emulsion.11. The composition according to claim 7 , wherein said intralipid-iodine absorbs/attaches obstructive or potentially-obstructive particles located within blood vessels and/or other organs in the body claim 7 , and removes same to thereby open clogged blood vessels.12. A method for imaging comprising administering to an individual in need thereof an effective amount of the intralipid-iodine of .13. The method according to claim 12 , comprising injecting said intralipid-iodine or said composition comprising same into the blood stream of said individual.14. The method according to claim 12 , wherein said intralipid-iodine is any lipid emulsion.15. The method ...

LIQUID EMBOLIC AGENT COMPOSITION

Provided is a liquid embolic agent composition capable of solving problems of conventional embolic agents, which can be used in a treatment of a vascular disease such as cerebral aneurysm. The problems are solved by a liquid embolic agent composition characterized in containing a hydrogel forming component having a calcium ion entrapping ability, and an anti-biodegradation component. The hydrogel forming component having a calcium ion entrapping ability is at least one kind of acidic polysaccharide selected from the group consisting of alginate, gellan gum, carrageenan, and carboxymethyl cellulose salt; and the anti-biodegradation component is at least one kind selected from the group consisting of hydroxypropyl methylcellulose, methylcellulose, polyvinyl alcohol, polyallylamine, poly-N-vinyl acetamide, and cellulose acetate. 19-. (canceled)10. A liquid embolic agent composition which comprises:a hydrogel forming component having a calcium ion entrapping ability; andan anti-biodegradable component,wherein the hydrogel forming component having a calcium ion entrapping ability comprises sodium alginate and gellan gum,wherein the anti-biodegradable component is hydroxypropyl cellulose, andwherein the liquid embolic agent composition is in a liquid state in vitro, and gelates by reacting with calcium ions in blood to exhibit a bioadhesiveness in vivo.11. The liquid embolic agent composition according to claim 10 , further comprising a coagulation promoting component claim 10 , wherein the coagulation promoting component is at least one selected from the group consisting of colloidal silica claim 10 , poly(N claim 10 ,N-dimethyl) acrylamide claim 10 , an enzyme preparation for food processing claim 10 , poly-L-lysine hydrobromide claim 10 , poly-L-glutamic acid sodium salt claim 10 , chitosan claim 10 , and silk fibroin.12. The liquid embolic agent composition according to claim 10 , which is used for treating cerebral aneurysm.13. The liquid embolic agent composition ...

SYSTEMS, METHODS, AND DEVICES FOR MEDICAL IMAGE ANALYSIS, DIAGNOSIS, RISK STRATIFICATION, DECISION MAKING AND/OR DISEASE TRACKING

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and/or dynamically identify one or more features, such as plaque and vessels, and/or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and/or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and/or quantified parameters. 1. A method for displaying computed tomography (CT) images and corresponding coronary vessel information including images rendered from the CT images , and identification and measurements of lumen , vessel walls and plaque of coronary vessels determined from the CT images by image processing , the method comprising:storing computer-executable instructions, a set of CT images of a patient's coronary vessels, and coronary vessel information associated with the set of CT images on a non-transitory computer readable medium, the coronary vessel information including information of plaque and locations of segments of the coronary vessels;generating and displaying in a user interface a first panel including a representation of coronary vessels using the coronary vessel information, the representation of coronary vessels depicting coronary vessels identified in the set of CT images;receiving a first input in the first panel indicating a selection of a coronary vessel of the representation of coronary vessels;in response to the first input, generating and displaying on the user interface a second panel illustrating at least a portion of the selected coronary ...

Imaging composition comprising porous silicon micro-particles

The present disclosure describes an imaging composition including porous silicon microparticles, and more particularly, to a biological tissue imaging composition including a composite in which oxidized porous silicon microparticles and silver nanoparticles are combined. Since a biological tissue imaging agent of the present invention, which includes a composite of oxidized porous silicon microparticles and silver nanoparticles, continuously provides an image signal without spreading in the body as compared to conventional imaging agents, it is possible to increase surgical stability by accurately identifying target tissues in vivo in an affected area.

ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE

The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same. 156.-. (canceled)57. A method of treating an individual having an Ly6E-positive cancer , the method comprising administering to the individual an effective amount of an immunoconjugate comprising an isolated monoclonal antibody that binds to Ly6E and a cytotoxic agent , wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:10; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:11; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:12; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:7; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:8; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:9.58. The method of claim 57 , wherein the Ly6E-positive cancer is selected from a breast cancer claim 57 , pancreatic cancer claim 57 , colon cancer claim 57 , colorectal cancer claim 57 , melanoma claim 57 , ovarian cancer claim 57 , non-small cell lung cancer claim 57 , or gastric cancer.59. The method of claim 57 , further comprising administering an additional therapeutic agent to the individual.60. The method of claim 57 , wherein the additional therapeutic agent is a platinum complex.61. The method of claim 57 , wherein the immunoconjugate has the formula Ab-(L-D)p claim 57 , wherein:(a) Ab is the antibody;(b) L is a linker;(c) D is a cytotoxic agent selected from a maytansinoid, an auristatin, a calicheamicin, a pyrrolobenzodiazepine, and a nemorubicin derivative; and(d) p ranges from 1-8.62. The method of claim 57 , wherein the cytotoxic agent is an auristatin.64. The method of claim 57 , wherein the cytotoxic agent is MMAE.65. The method of claim 57 , wherein the cytotoxic agent is a pyrrolobenzodiazepine.68. The method of claim 57 , wherein the cytotoxic agent is a nemorubicin derivative.70. The method of claim 61 , wherein the linker is cleavable by a protease.71. The method of claim 61 , wherein ...

Water-Equivalent Phantom

A composition for use in radiology includes glass micro bubbles, Araldite, Jeffamine, magnesium oxide, and polyethylene. Another composition or use in radiology may include glass micro bubbles, an epoxy, acrylic, or polyurethane, and polyethylene. This composition may result in an elemental composition including carbon, oxygen, hydrogen, nitrogen, calcium, and magnesium. A composition for use in radiology may include glass micro bubbles, araldite, jeffamine, calcium carbonate, magnesium oxide, polyethylene, and a pigment and the composition includes an elemental composition including carbon, oxygen, hydrogen, nitrogen, calcium, silicon, and magnesium. 1. A composition for use in radiology comprising: 2.9-3.3% Glass Micro Bubbles (w/w) , 54-67% Araldite (w/w) , 20-33% Jeffamine (w/w) , 3-5% CaCO(w/w) , 1-3% MgO (w/w) , and 8-12% Polyethylene (w/w).2. The composition of claim 1 , wherein the elemental composition comprises of 64-67% carbon (w/w) claim 1 , 18-21% oxygen (w/w) claim 1 , 7-10% hydrogen (w/w) claim 1 , 1-3.5% nitrogen (w/w) claim 1 , 0.5-3% calcium (w/w) claim 1 , 0.5-2.5% magnesium (w/w).3. The composition of claim 2 , wherein the elemental composition further comprises at least one of silicon claim 2 , chlorine claim 2 , boron claim 2 , aluminum claim 2 , sodium and sulfur.4. The composition of claim 3 , wherein the silicon is at a concentration of 0.1-2.5% (w/w) claim 3 , and each of the chlorine claim 3 , boron claim 3 , aluminum claim 3 , sodium and sulfur are present at a concentration of less than 1% (w/w).5. The composition of claim 3 , wherein the composition comprises silicon claim 3 , chlorine claim 3 , boron claim 3 , aluminum claim 3 , sodium and sulfur at concentrations of less than 2% (w/w).6. The composition of claim 1 , further comprising a pigment at a concentration of 0-1.5% (w/w).7. The composition of claim 6 , wherein the pigment is selected from NaAlSiOSor SiO(OH)Mg—CoCa—Al.8. The composition of claim 1 , wherein the composition has ...

SETTING OF HARDENABLE BONE SUBSTITUTE

The invention relates to hardenable ceramic bone substitute compositions having improved setting, powders for such compositions and methods for their manufacture and use in medical treatment. More specifically the invention relates to hardenable bone substitute powder and hardenable bone substitute paste with improved setting properties, comprising calcium sulfate and heat-treated hydroxyapatite (passivated HA), which bone substitute is suitable for treatment of disorders of supportive tissue such as bone loss, bone fracture, bone trauma and osteomyelitis.

HYBRID MEMBRANE-COATED NANOPARTICLE COMPOSITES AND METHODS OF MAKING AND USING THE SAME

Disclosed herein are embodiments of nanoparticle composites that comprise covalently coupled stabilizing agent molecules that improve stability of the nanoparticle composites and allow for tight packing of lipids and/or membranes. The nanoparticle composites can further comprise inhibition inhibitors and/or lipid components that interact to form a hybrid lipid bilayer membrane around the nanoparticle core. The nanoparticle composites can be coupled to drugs, targeting moieties, and imaging moieties. The nanoparticle composites can be used for in vivo drug deliver, disease diagnosis/treatment, and imaging. 1. A nanoparticle composite , comprising:one or more lipid molecules;one or more aggregation inhibitors;one or more stabilizing agent molecules comprising a heteroatom group and an aliphatic chain; anda nanoparticle core, comprising iron, silver, gadolinium, or a combination or oxide thereof; wherein the nanoparticle core is covalently coupled to the one or more stabilizing agent molecules through the heteroatom group of the one or more stabilizing agent molecules.2. The nanoparticle composite of claim 1 , wherein the one or more aggregation inhibitors comprises (i) a hydrophobic chain and (ii) a polar terminus that is not covalently attached to the surface of the nanoparticle core.3. The nanoparticle composite of claim 2 , wherein the hydrophobic chain comprises two to 20 carbon atoms.4. The nanoparticle composite of claim 2 , wherein the polar terminus comprises a carboxylate group claim 2 , a tetra-substituted ammonium group claim 2 , a phosphate group claim 2 , or a combination thereof.5. The nanoparticle composite of claim 1 , wherein the one or more aggregation inhibitors is oleic acid claim 1 , oleate claim 1 , or a mixture thereof; or L-α-phosphatidylcholine.6. The nanoparticle composite of claim 1 , wherein the one or more lipids and the one or more aggregation inhibitors have the same structure.7. The nanoparticle composite of claim 1 , wherein the one or ...

Process for manufacture of gadofosveset trisodium monohydrate

This application relates to a process for making a pharmaceutically acceptable formulation of gadofosveset trisodium monohydrate, wherein the process uses no more than one chromatographic purification for removal of impurities.

Bolus Imaging

A system and method includes detection of a trigger event, automatic injection, in response to detecting the trigger event, of a bolus of contrast medium into a patient volume after expiration of a predetermined injection delay period, automatic acquisition, in response to detecting the trigger event, of a plurality of images after expiration of a predetermined imaging delay period, where two or more of the plurality of images comprise an image of the bolus at respective different locations within vasculature of the patient volume, generation of a composite image based on the plurality of images, the composite image including a representation of the vasculature of the patient volume, and display of the composite image. 1. A system comprising: detect a trigger event;', 'in response to detection of the trigger event, automatically inject a bolus of contrast medium into a patient volume after expiration of a predetermined injection delay period;', 'in response to detection of the trigger event, automatically acquire a plurality of images after expiration of a predetermined imaging delay period, two or more of the plurality of images comprising an image of the bolus at respective different locations within vasculature of the patient volume; and', 'generate a composite image based on the plurality of images, the composite image including a representation of the vasculature of the patient volume; and, 'a processing unit toa display to display the composite image.2. A system according to claim 1 , wherein each of the plurality of images is acquired at a predefined imaging interval claim 1 , and wherein a distance traveled by the bolus in the vasculature during the predefined imaging interval is greater than a dimension of the bolus in the direction of travel.3. A system according to claim 1 , wherein generation of the composite image comprises:identification of a location of the bolus in the two or more of the plurality of images;determination of a curve connecting the ...

CONTRAST MEDIUM FOR MICROANGIOGRAPHY

The invention relates to a contrast medium for ex vivo microangiography for digital imaging of the vascular system of a mouse or rat or other laboratory animals, and of individual animal and human organs, comprising an iodized, esterified oil, a polyurethane, and a hardener. The invention further relates to a method for producing the contrast medium; to a kit of parts, comprising the various containers having the components of the contrast medium according to the invention that are to be mixed; and to a preferred use of the contrast medium according to the invention for imaging by means of a micro-CT device. 1. A contrast agent for ex vivo micro angiography , for the digital imaging of a vascular system of a mouse or a rat or other laboratory animals , or of individual animal- and human organs , by means of a micro-CT-device , comprising:a polyurethane,a hardener,iodized, esterified oil, anda ketone.2. The contrast agent according to claim 1 , wherein the iodized claim 1 , esterified oil is an iodized claim 1 , esterified poppy seed oil claim 1 , or an iodized claim 1 , esterified linseed oil.3. The contrast agent according to claim 1 , wherein the ketone is selected from 2-butanone claim 1 , acetone claim 1 , or 3-pentanone.4. The contrast agent according to claim 1 , wherein the contrast agent comprises a dye.5. The contrast agent according to claim 1 , wherein the polyurethane is an aliphatic isocyanate.6. The contrast agent according to claim 1 , wherein the hardener is a modified claim 1 , aromatic diamine.7. The contrast agent according to claim 1 , wherein:the iodized, esterified oil is contained at 20-60% in the contrast agent; andthe ketone is contained at 7-30% in the contrast agent.8. The contrast agent according to claim 1 , wherein in a contrast solution claim 1 , which comprises the iodized claim 1 , esterified oil and the ketone claim 1 , the ratio of the volume of the iodized claim 1 , esterified oil to the volume of the ketone is 0.75-4.9. The ...

SYSTEMS AND METHODS FOR IMAGING SINUSES

Systems, devices, and methods for imaging a sinus in a patient involving a through sinus are presented. In one instance, a system includes a radiopaque wound filler for disposing into the through sinus. The system further includes a radiopaque solution for deploying into the sinus, and a radiopaque solution unit having a radiopaque solution reservoir and a positive pressure source. Other systems, devices, and methods are presented. 1. A method for imaging a sinus that includes a through sinus in a patient , the method comprising:disposing a radiopaque wound filler into the through sinus, wherein the radiopaque wound filler includes a first radiopaque marker to present a first contrast in a sinographic image;deploying a radiopaque solution into the sinus; andcapturing a sinographic image of the sinus in which the first radiopaque marker of the radiopaque wound filler presents the first contrast and the radiopaque solution presents a second contrast.2. The method of claim 1 , further comprising identifying a hidden sinus by identifying areas having the second contrast and not the first contrast.3. The method of claim 1 , further comprising applying reduced pressure to the sinus.4. The method of claim 1 , wherein:the step of deploying the radiopaque solution comprises introducing the radiopaque solution using positive pressure;wherein the radiopaque wound filler comprises a reduced pressure manifold; andfurther comprising applying reduced pressure to the sinus.5. The method of claim 4 , wherein the sinus has a first opening and a second opening claim 4 , and wherein the radiopaque solution is introduced through the first opening and the reduced pressure is introduced through the second opening.6. The method of claim 4 , wherein the sinus has a first opening and wherein the radiopaque solution is introduced through the first opening and the reduced pressure is introduced through the first opening.7. A method for imaging a sinus in a patient claim 4 , the method ...

ANTI-MACROPHAGE MANNOSE RECEPTOR SINGLE VARIABLE DOMAINS FOR USE IN CARDIOVASCULAR DISEASES

The disclosure relates to the field of cardiovascular diseases. In particular, immunoglobulin single variable domains directed against macrophage mannose receptor (MMR) are provided that can be used in the diagnosis, prognosis and/or monitoring of cardiovascular diseases or as therapeutics. Also, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are useful at different stages of cardiovascular diseases, including post-infarction cardiovascular events. Further, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are particularly useful for the in vivo targeting and/or imaging of vulnerable atherosclerotic plaques. 1. A method of diagnosing and/or prognosing a cardiovascular disease in a subject , the method comprising:utilizing an anti-macrophage mannose receptor (anti-MMR) immunoglobulin single variable domain to diagnose and/or prognose the subject's cardiovascular disease.2. The method according to claim 1 , wherein said anti-MMR immunoglobulin single variable domain is coupled to a detectable label.3. The method according to claim 2 , wherein said detectable label is a radionuclide.4. The method according to claim 1 , wherein the anti-MMR immunoglobulin single variable domain is a contrast agent in non-invasive in vivo medical imaging.5. The method according to claim 1 , wherein said cardiovascular disease is atherosclerosis.6. The method according to claim 1 , the method further comprising:targeting and/or detecting vulnerable atherosclerotic plaques in the subject.7. The method according to claim 1 , the method further comprising:monitoring the degree of vulnerability of atherosclerotic plaques and/or the evolution in function of time of the degree of vulnerability of atherosclerotic plaques.8. The method according to claim 1 , for use in the subject post-infarction.9. The method according to claim 8 , wherein said cardiovascular disease is cardiac remodeling or ...

EXENDIN-4 PEPTIDE ANALOGUES AS DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake 2. The compound of claim 1 ,which is a GLP1 and Glucagon receptor agonist.3. The compound according to any one of claim 1 , wherein Ris NH.4. The compound of claim 1 , wherein the peptidic compound has a relative activity of at least 0.1% compared to that of natural glucagon at the glucagon receptor.5. The compound of claim 1 , wherein the peptidic compound exhibits a relative activity of at least 0.1% compared to that of GLP-1(7-36) at the GLP-1 receptor.6. The compound of claim 1 , whereinX2 represents an amino acid residue selected from Ser, D-Ser or Aib,X3 represents an amino acid residue selected from Gln or His,X18 represents ArgX20 represents an amino acid residue selected from Lys, Gln, His, or (S)MeLys,X21 represents an amino acid residue selected from Asp or Glu,X28 represents an amino acid residue selected from Ser or Ala, andX32 represents an amino acid residue selected from Ser or Val.7. The compound of claim 1 , whereinX2 represents an amino acid residue selected from Ser, D-Ser or Aib,X3 represents an amino acid residue selected from Gln or His,X18 represents an amino acid residue selected from Arg or Lys,X20 represents Lys,X21 represents an amino acid residue selected from Asp or Glu,X28 represents an amino acid residue selected from Ser or Ala, andX32 represents an amino acid residue selected from Ser or Val.8. The compound of claim 1 , whereinX2 represents an amino acid residue selected from Ser, D-Ser or Aib,X3 represents Gln,X18 represents Arg,X20 represents (S)MeLys,X21 represents Asp,X28 represents Ala, andX32 represents an amino acid residue selected from Ser or Val.9. The compound of claim 1 , whereinX2 represents Aib,X3 represents Gln,X18 represents Arg,X20 represents an amino acid residue selected from Lys or Gln,X21 ...

Polymeric treatment compositions

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological pH solution; wherein the biocompatible polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

GOLD NANOPARTICLES AND ECOLOGICAL METHOD OF PRODUCTION

A method of preparing biocompatible and stable gold nanoparticles comprises preparing at least one flavonoid-rich plant extract, and mixing at least one of the plant extracts with an aqueous solution of at least one gold salt. The flavonoid-rich plant extract is an extract of or . The gold nanoparticles may be used for medical and/or cosmetic purposes. 1. A method of preparing biocompatible and stable gold nanoparticle , comprising:preparing at least one flavonoid-rich plant extract; andmixing at least one of the plant extracts with an aqueous solution of at least one gold salt,{'i': Hubertia ambavilla', 'Hypericum lanceolatum., 'wherein the flavonoid-rich plant extract is an extract of or'}2. The method according to claim 1 , wherein the flavonoid-rich plant extract is a total crude extract of the plant or the flavonoids of the plant.3. The method of claim 1 , wherein the plant extract comprises flavonoids selected from among rutin claim 1 , quercetin claim 1 , hyperoside and isoquercetin or a combination of at least two thereof.4. The method of claim 1 , wherein the nanoparticles have a diameter of between 5 and 100 nm.5. The method of claim 1 , wherein the nanoparticles are spherical claim 1 , and the nanoparticles are obtained by mixing plant flavonoids with an aqueous solution of at least one gold salt.6. The method of claim 1 , wherein the nanoparticles are anisotropic and flower-shaped claim 1 , and the flower-shaped gold nanoparticles are obtained by mixing a total crude plant extract with an aqueous solution of at least one gold salt.7Hubertia ambavillaHypericum lanceolatum.. An anisotropic flower-shaped gold nanoparticle comprising a mixture of gold and crude extract of or8. The nanoparticle of claim 7 , wherein the diameter of the nanoparticle is between 40 nm and 80 nm when measured by transmission electron microscopy.9. The nanoparticle of claim 7 , wherein the nanoparticle is functionalized by proteins.10. A medicinal product comprising a nanoparticle ...

BLOOD-BRAIN BARRIER VECTOR COMPOUNDS AND CONJUGATES THEREOF

Provided are vector compounds that bind to N-acetylated-alpha-linked acidic dipeptidase-like protein 2 (NAALADL2), and related conjugates, compositions, methods of use thereof, and methods of screening for and identifying the same, for instance, to facilitate delivery of therapeutic or diagnostic agents across the blood-brain barrier (BBB) and/or improve tissue penetration in CNS and peripheral tissues, and thereby treat and/or various diseases, including those of the central nervous system (CNS). 1. A conjugate , comprising: (a) a vector compound that specifically binds to N-acetylated-alpha-linked acidic dipeptidase-like protein 2 (NAALADL2); and (b) a therapeutic or diagnostic agent , where (a) and (b) are covalently or operatively linked to form the conjugate , where the vector compound is not a melanotransferrin (MTf) polypeptide.2. The conjugate of claim 1 , where NAALADL2 is human NAALADL2.3. The conjugate of claim 1 , where NAALADL2 comprises SEQ ID NO:1.4. The conjugate of any of the preceding claims claim 1 , where the vector compound specifically binds to an extracellular domain of NAALADL2.5. The conjugate of claim 4 , where the vector compound specifically binds to a region of residues 143-795 of SEQ ID NO:1.6. The conjugate of any of the preceding claims claim 4 , where vector compound is effective for transporting the therapeutic or diagnostic agent across a blood brain barrier (BBB).7. The conjugate of any of the preceding claims claim 4 , where specific binding of the vector compound to NAALADL2 is effective for transporting the therapeutic or diagnostic agent across a blood brain barrier (BBB).8. The conjugate of any of the preceding claims claim 4 , where the vector compound is a polypeptide or a small molecule.9. The conjugate of claim 8 , where the polypeptide is an antibody or antigen-binding fragment thereof.10. The conjugate of claim 8 , where the polypeptide is a peptide of up to about 50 amino acids in length.11. The conjugate of any of - ...

PERIODIC CONTRAST INJECTIONS AND ANALYSIS OF HARMONICS FOR INTERVENTIONAL X-RAY PERFUSION IMAGING

An apparatus () and a method for adjusting, in perfusion imaging system, a periodic contrast agent injection rate signal (IS) for an injector () as function of an image sampling rate determined by the rotational speed of an X-ray source ()-detector () assembly of an X-ray imager (). Frequency, periodicity and pulse width of the contrast agent injection rate signal (IS) is adjusted to mitigate temporal signal aliasing in a sample of a time attenuation contrast (TAC) signal. 1. An apparatus for supporting perfusion imaging , comprising:an input interface for receiving a frequency for an oscillatory motion of an X-ray scanner's X-ray source around an object during a perfusion imaging session where a sequence of projection images are acquired of the object whilst contrast agent is at least partly perfusing at least a region of the object, the perfusion resulting in an X-ray attenuation signal (TAC) for that object region, the received frequency of the X-ray source's oscillatory motion defining a sampling rate for the X-ray attenuation signal (TAC), image points across the acquired sequence of projection images representing a temporal sample of said X-ray attenuation signal (TAC) for the object region;a control unit configured to use the received sampling frequency to generate a control signal for an injector unit to deliver the contrast agent to the object at a discharge rate, the control signal, when applied to the injector unit, causing the contrast agent injection rate to vary over time according to a periodic signal of pulses, the period of the pulsed signal computed by the controller so as to mitigate temporal signal aliasing in the X-ray attenuation signal sample.2. Apparatus of claim 1 , the controller configured to mitigate the aliasing by adjusting the frequency of at least one of the pulsed injection rate signal's harmonics so that the adjusted frequency of the at least one harmonic differs by at least a user-definable/preset margin from each of the ...

BI-DOTA COMPLEX-LOADED DENDRITIC POLYMER NANOPARTICLES

Disclosed are compositions comprising polymeric nanoparticles and methods of using the same. The polymeric nanopartides can be conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein. The polymeric nanoparticles can also comprises an imaging compound and/or a therapeutic agent encapsulated in the hydrophobic interior of the nanoparticle. A cancer therapeutic composition comprising the nanoparticle is also disclosed. The disclosed nanoparticles can be used to target and deliver imaging and/or therapueitc compounds to cancer cells, thereby identifying and/or treating a solid tumor cell target. Methods for treating cancer, such as lung cancer, using the polymeric nanoparticles are also disclosed. 2. A polymeric nanoparticle comprising the polymer of .3. The polymeric nanoparticle of claim 2 , wherein the polymeric nanoparticle is biodegradable.4. The polymeric nanoparticle of claim 2 , having one or more internal hydrophobic pockets and a hydrophilic outer surface.5. The polymeric nanoparticle of claim 2 , further comprising a hydrophobic near-infrared fluorescent dye encapsulated therein.6. The polymeric nanoparticle of claim 5 , wherein the near-infrared fluorescent dye is selected from the group consisting of DiI claim 5 , DiR claim 5 , DiD claim 5 , and combinations thereof.7. The polymeric nanoparticle of claim 2 , further comprising one or more therapeutic drugs encapsulated therein.8. The polymeric nanoparticle of claim 2 , wherein the therapeutic drug comprises an anti-cancer drug.9. The polymeric nanoparticle of claim 7 , further comprising a fluorescent dye co-encapsulated with said therapeutic drug.10. The polymeric nanoparticle of claim 2 , further comprising one or more imaging compounds encapsulated therein.11. The polymeric nanoparticle of claim 2 , further comprising one or more therapeutic drugs and one or more imaging compounds.12. The polymeric nanoparticle of claim 2 , further comprising a targeting ligand.13. ...

Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods ofpreparing and using the same

Polymeric particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene and/or a derivative thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in specific selected sizes to allow for selective embolization of certain sized blood vessels or localized treatment with an active component agent in specific clinical uses. Particles of the present invention may further be provided as color-coded microspheres or nanospheres to allow ready identification of the sized particles in use. Such color-coded microspheres or nanospheres may further be provided in like color-coded delivery or containment devices to enhance user identification and provide visual confirmation of the use of a specifically desired size of microspheres or nanospheres.

COMPOSITION FOR HARD TISSUE REPAIR AND KIT FOR HARD TISSUE REPAIR

The application discloses a composition for hard tissue repair comprising a monomer (A), a polymer powder (B) and a polymerization initiator (C), wherein the polymer powder (B) comprises a polymer powder (B-x) having an aspect ratio of 1.10 or more, and the cumulative ratio of powder particles having aspect ratios of 1.00 or more and less than 1.10 in all of the powder particles contained in the composition for hard tissue repair is 75 cumulative % or less, as well as, a kit for hard tissue repair comprising three or more members, in which each of the components of the monomer (A), the polymer powder (B) and the polymerization initiator (C) contained in this composition for hard tissue repair are divided and contained in the members in an optional combination. 1. A composition for hard tissue repair comprising a monomer (A) , a polymer powder (B) and a polymerization initiator (C) , whereinthe polymer powder (B) comprises a polymer powder (B-x) having an aspect ratio of 1.10 or more, andthe cumulative ratio of powder particles having aspect ratios of 1.00 or more and less than 1.10 in all of the powder particles contained in the composition for hard tissue repair is 75 cumulative % or less.2. The composition for hard tissue repair according to claim 1 , wherein the cumulative ratio of powder particles having aspect ratios of 1.00 or more and less than 1.10 in all of the powder particles contained in the composition for hard tissue repair is 2.5 cumulative % or more claim 1 , and 65 cumulative % or less.3. The composition for hard tissue repair according to claim 1 , wherein the polymer powder (B) comprises a polymer powder (B-x) having an aspect ratio of 1.10 or more and 1.90 or less claim 1 , and the aspect ratio of all of the polymer powder (B) is 1.11 or more and 1.80 or less.4. The composition for hard tissue repair according to claim 1 , wherein the monomer (A) is a (meth)acrylate-based monomer.5. The composition for hard tissue repair according to claim 1 , ...

POLYMERIC TREATMENT COMPOSITIONS

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological solution; wherein the biocompatible polymer is soluble in the non-physiological solution and insoluble in a physiological solution. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use. 1. A polymeric composition comprising: 'a first monomer including a biodegradable linkage to a visualization agent, and a second monomer including at least one hydroxyl group; and', 'a substantially stable biocompatible polymer comprising a reaction product ofwherein the substantially stable biocompatible polymer is dissolved in a solution.2. The polymeric composition of claim 1 , wherein the visualization agent includes at least one aromatic ring.3. The polymeric composition of claim 2 , wherein the at least one aromatic ring at least one iodine atom.4. The polymeric composition of claim 1 , wherein the solution is a non-physiological solution.5. The polymeric composition of claim 4 , wherein the non-physiological solution is a water miscible solvent.6. The polymeric composition of claim 5 , wherein the concentration of the substantially stable biocompatible polymer in the water miscible solvent is about 1% to about 50%.7. The polymeric composition of claim 1 , wherein the second monomer is hydroxyethyl methacrylate.8. The polymeric composition of claim 1 , wherein the biodegradable linkage is Seq. ID 1 claim 1 , Seq. ID 2 claim 1 , Seq. ID 3 claim 1 , Seq. ID 4 claim 1 , Seq. ID 5 claim 1 , Seq. ID 6 claim 1 , Seq. ID 7 claim 1 , Seq. ID 8 claim 1 , Seq. ID 9 claim 1 , Seq. ID 10 claim 1 , Seq. ID 11 claim 1 , or Seq. ID 12.9. The polymeric composition of claim 1 , wherein the biodegradable linkage is an ester or a polyester.10. The polymeric composition of claim 1 , wherein the substantially stable biocompatible polymer is a reaction product of 2-oxo-2-(1-oxo-1-(1-oxo-1-(2 claim 1 ,4 ...

FOXC1 ANTIBODIES AND METHODS OF THEIR USE

In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided. 120-. (canceled)22. The antibody or functional fragment of claim 21 , wherein the antibody or functional fragment thereof is a monoclonal antibody.23. The method of claim 21 , wherein the biological sample is a primary or metastatic tumor sample claim 21 , a blood sample claim 21 , a serum sample claim 21 , a plasma sample claim 21 , a lymph sample claim 21 , a lymph node sample claim 21 , a cerebrospinal fluid sample claim 21 , a bone marrow sample claim 21 , an interstitial fluid sample or a urine sample.24. The method of claim 21 , wherein the antibody or functional fragment thereof is conjugated to a diagnostic agent.25. The method of claim 24 , wherein the diagnostic agent is a radioactive substance claim 24 , dyes contrast agent claim 24 , fluorescent compound or molecule claim 24 , bioluminescent compound or molecule claim 24 , enzyme or enhancing agent.26. The method of claim 21 , wherein detecting the presence or absence of FOXC1 is accomplished by an in vitro immunoassay.27. The method of claim 26 , wherein the in vitro immunoassay is immunocytochemistry (ICC) claim 26 , immunohistochemistry (IHC) claim 26 , Western blot or fluorescent in situ hybridization (FISH).28. The method of claim 21 , further comprising:lysing or permeabilizing the one or more breast cancer cells when the in vitro immunoassay uses the contents of whole cells or whole cell preparations. This application is a continuation of U.S. patent application Ser. No. 15/293,117, ...

MULTIPURPOSE MEDICAL IMAGE INDICATOR AND METHOD FOR MANUFACTURING THE SAME

The present disclosure concerns a medical image indicator. More particularly, it concerns the multipurpose medical image indicator including more than one of fluorophores and MRI contrast agent/CT contrast agent and method for manufacturing same. Responding to a demand for non-invasive and effective way of marking lesions, the present disclosure provides a method for manufacturing the multipurpose medical image indicator including a provision of rubber material fluid composition; a mixing of the rubber material fluid composition and fluorophores; and a transfiguring and drying of the mixture and the multipurpose medical image indicator manufactured according to the method. Further, the present disclosure provides a ligation device for endoscope including the multipurpose medical image indicator. 1. Multipurpose medical image indicator including rubber material and fluorophores.2. Multipurpose medical image indicator of claim 1 ,wherein the rubber material is one of rubber, latex-free rubber, NFR, Neoprene, natural latex, and synthesis latex.3. Multipurpose medical image indicator of claim 1 ,wherein the fluorophores includes more than one of Indocyanine Green, Rose Bengal, dye affiliated with ATTO, dye affiliated with Alexa, Rhodamine, Fluorescein, Cumarin, Naphthalimide, Benzoxanthen and Acridine4. Multipurpose medical image indicator according to any of to claim 1 , further comprising claim 1 , MRI (Magnetic Resonance Imaging) contrast agent.5. Multipurpose medical image indicator of claim 4 ,wherein the MRI contrast agent is composed of a gadolinium complex, a mangan complex, or an oxidized steel nanoparticle.6. Multipurpose medical image indicator according to any of to claim 4 , further comprising claim 4 , CT (computer tomography) contrast agent.7. Multipurpose medical image indicator of claim 6 ,wherein the CT contrast agent is composed of a metal, a complex including iodine, or a nanoparticle.8. A method for manufacturing multipurpose medical image indicator ...

RADIOPAQUE CONTRAST AGENT

A radiopaque composition is provided that includes an inorganic opacifying agent distributed through an aqueous gelatinous substance in an aqueous solvent. A process for making a radiodense vascular fill composition includes adding a gelatinous substance to an aqueous solution. An inorganic opacifying agent suspension is formed in a saline solution or water. The inorganic opacifying agent and gelatin are mixed with water or saline. A process of imaging a vascular system of a subject includes placing a subject under anesthesia or sedation and exsanguinating the subject. An isotonic fluid is then flushed through the vascular system and the radiopaque composition is infused into the subject circulatory system at a temperature of 40 degrees Celsius or greater. After waiting a given time interval for the radiopaque composition to cool and form a solid gel, an imaging scan is performed on the subject. 1. A radiopaque composition comprising:an inorganic opacifying agent having a size of less than 40 microns;an aqueous gelatinous substance of gelatin, where the gelatin is present in an amount of 5 percent weight by volume or more; andan aqueous solvent.2. The composition of wherein said inorganic opacifying agent is present in from 10 to 25 percent weight by volume.3. The composition of wherein said gelatin is present from 5 to 20 percent weight by volume.4. The composition of wherein said inorganic opacifying agent is barium sulfate or barium titanate.5. The composition of further comprising an inorganic metal salt soluble in said aqueous solvent.6. The composition of wherein said inorganic metal salt is at least one of aluminum trihydroxide claim 5 , bismuth iodide claim 5 , silver nitrate.7. The composition of wherein said inorganic opacifying agent is stainless iron oxide claim 1 , zinc oxide claim 1 , elemental iodine claim 1 , or a combination thereof.8. The composition of wherein said an inorganic opacifying agent has a median particle size of from 5 nanometers to 15 ...

IMAGEABLE EMBOLIC MICROSPHERE

This invention concerns imageable, radiopaque embolic beads, which are particularly useful for monitoring embolization procedures. The beads comprise iodine containing compounds which are covalently incorporated into the polymer network of a preformed hydrogel bead. The beads are prepared by activating pre-formed hydrogel beads towards nucleophilic attack and then covalently attaching iodinated compounds into the polymer network. The radiopaque beads may be loaded with chemotherapeutic agents and used in methods of embolizing hyperplastic tissue or solid tumors. 1. An activated hydrogel bead which has been activated towards nucleophilic substitution reaction with carbonyl diimidazole or carbodiimide.2. An activated hydrogel bead according to in which the hydrogel comprises a polyhydroxy polymer such as polyvinyl alcohol (PVA) or copolymers of vinyl alcohol.3. An activated hydrogel bead according to or in which the hydrogel has a polymer backbone with a 1 claim 1 ,2-diol and/or a 1 claim 1 ,3-diol structure to enable crosslinking with an acrylic monomer.4. An activated hydrogel bead according to in which the acrylic monomer is 2-acrylamido-2-methylpropane sulfonic acid (AMPS).5. An activated hydrogel bead according to any of to in which hydroxyl moieties on and/or within the preformed hydrogel bead are activated by reaction with carbonyldiimidazole.6. A method of activating a hydrogel bead towards nucleophilic substitution comprising the steps of: (i) suspending hydrogel beads in organic solvent until they have swollen; (ii) adding carbonyldiimidazole or a carbodiimide to the suspension of swollen beads in solvent claim 3 , in the presence of a catalytic amount of a base and under anhydrous conditions to achieve activation.7. A method according to which further comprises step (iii) in which the activated beads are filtered and washed with organic solvent to provide purified activated beads.8. A radiopaque hydrogel bead comprising the activated hydrogel bead of any of ...

RECOMBINANT SELF-ASSEMBLING PROTEIN COMPRISING TARGET-ORIENTED PEPTIDE AND USE THEREOF

The present invention relates to a recombinant self-assembled protein comprising a target-oriented peptide and a use thereof The recombinant self-assembled protein according to the present invention, comprising a target-oriented peptide, does not require an additional process for providing target-orientedness, and is thus capable of delivering a desired drug to a target tissue or target cell without using additives, such as chemical binders or stabilizers; therefore, the protein can be used for photothermal therapy, drug delivery, imaging, or the like. In particular, according to the present invention, it is possible to prepare gold-protein nanoparticle fusions in which uniform high-density gold nanoparticles having target-orientedness are bound to protein surfaces, without an additional process of surface stabilization or process for providing target-orientedness. Compared with conventional gold nanoparticles, the gold-protein nanoparticle fusions according to the present invention show structural stability against pH variation and concentration variation, and also have excellent target-orientedness; therefore, the fusions can bring a dramatic enhancement to the utilization of gold nanoparticles in photothermal therapy. 1. A recombinant self-assembled protein , comprising a target-oriented peptide fused to a self-assembled protein.2. The recombinant self-assembled protein of claim 1 , wherein the self-assembled protein is ferritin or hepatitis B virus (HBV) capsid protein.3. The recombinant self-assembled protein of claim 1 , wherein the target-oriented peptide is a cancer-targeting peptide ligand.4. A recombinant self-assembled protein nanoparticle claim 1 , comprising the recombinant self-assembled protein of .5. The recombinant self-assembled protein nanoparticle of claim 4 , wherein the target-oriented peptide is exposed on a surface of the recombinant self-assembled protein nanoparticle.6. The recombinant self-assembled protein nanoparticle of claim 5 , ...

CUPREDOXIN DERIVED TRANSPORT AGENTS AND METHODS OF USE THEREOF

The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer. 1. A peptide , consisting of a sequence that has at least about 90% amino acid sequence identity to less than a fill-length wild-type cupredoxin or H.8 outer membrane protein , and which facilitates the entry of a linked molecule into a mammalian cancer cell.2. The peptide of claim 1 , wherein the cupredoxin is selected from the group consisting of azurin claim 1 , plastocyanin claim 1 , rusticyanin claim 1 , pseudoazurin claim 1 , auracyanin and azurin-like protein.3Pseudomonas aeruginosa, Phormidium laminosum, Thiobacillus ferrooxidans, Achromobacter cycloclastes, Pseudomonas syringa, Neisseria meningitidis, Vibrio parahaemolyticus, Bordetella bronchiseptica, Bordetella pertussis, Chloroflexus aurantiacusNeisseria gonorrhoeae.. The peptide of claim 1 , wherein the peptide is derived from a organism selected from the group consisting of and4. The peptide of claim 1 , wherein the cupredoxin is selected from the group consisting of SEQ ID NO: 1 claim 1 , SEQ ID NO: 2 claim 1 , SEQ ID NO: 3 claim 1 , SEQ ID NO:4 claim 1 , SEQ ID NO: 29 claim 1 , SEQ ID NO: 30 claim 1 , SEQ ID NO: 31 claim 1 , SEQ ID NO: 32 claim 1 , SEQ ID NO: 33 claim 1 , SEQ ID NO: 34 claim 1 , SEQ ID NO: 36 and SEQ ID NO: 43.5. The peptide of claim 1 , which is at least about 10 residues and not more than about 50 residues in length.6. The peptide of claim 1 , comprising a sequence which has at least about 90% amino acid sequence identity to a sequence selected from the group consisting of SEQ ID NO: 5 claim 1 , SEQ ID NO: 6 claim 1 , SEQ ID NO: 7 claim 1 , SEQ ID NO: 9 claim 1 , SEQ ID NO: 37 claim 1 , SEQ ID NO: 38 claim 1 , SEQ ID NO: 39 claim 1 , SEQ ID NO: 40 claim 1 , SEQ ID NO: 41 claim 1 , ...

Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease

Disclosed are compositions comprising an antisense oligonucleotide and a non-ionic, low-osmolar contrast agent. Also disclosed are methods of delivering an antisense oligonucleotide to a target site comprising incorporating the antisense oligonucleotide into a composition comprising a non-ionic, low-osmolar contrast agent. Also disclosed are methods of treating a neurodegenerative disease comprising administering one or more of the compositions disclosed herein.

Capsule for Measuring Motility of a Target Area

A capsule for measuring motility of a target area is provided. An article of manufacture for measuring motility of a target area, comprises a first capsule and a second capsule. The a first capsule comprises a first capsule enclosure; a first identification marker, having a weight of W, wherein the first identification marker comprises a first visible element under X-ray, substantially circular shaped and having an outer diameter of A. The second capsule comprises a second capsule enclosure; a second identification marker, having a weight of W, wherein the second identification marker comprises a second visible element under X-ray, substantially circular shaped and having an outer diameter of B. The first capsule enclosure and second capsule enclosure are substantially identical under all measurements in digestive behaviors; the weight of the first identification marker Wand the weight of the second identification marker Wdiffers less than 0.01 g; A is less than B. 1. An article of manufacture for measuring motility of a target area , comprising a first capsule enclosure;', {'sub': 'm1', 'a first identification marker, having a weight of W, wherein the first identification marker comprises a first visible element under X-ray, substantially circular shaped and having an outer diameter of A;'}], 'a first capsule, comprises'} a second capsule enclosure;', {'sub': 'm2', 'a second identification marker, having a weight of W, wherein the second identification marker comprises a second visible element under X-ray, substantially circular shaped and having an outer diameter of B;'}, 'wherein', 'the first capsule enclosure and second capsule enclosure are substantially identical under all measurements in digestive behaviors;', {'sub': m1', 'm2, 'the weight of the first identification marker Wand the weight of the second identification marker Wdiffers less than 0.01 g;'}, 'the outer diameter of the first visible element under X-ray (A) is less than the outer diameter of the ...

Tantalum Oxide Nanoparticle Contrast Agents

A nanoparticle composition is provided. The nanoparticle composition includes a plurality of nanoparticles, each nanoparticle of the plurality having a core including tantalum oxide, and a covalent coating covalently bound to the core. The covalent coating includes a surface modifier selected from the group consisting of (3-aminopropyl)trimethoxy silane (APTMS), (3-aminopropyl)triethoxy silane (APTES), APTMS-methoxy-poly(ethylene-glycol)-succinimidyl glutarate (APTMS-m-PEG-glutarate), APTES-methoxy-poly(ethylene-glycol)-succinimidyl glutarate (APTES-m-PEG-glutarate), 2-[methoxy (polyethyleneoxy)-9-12-propyl] trimethoxysilane (PEG-Silane), hexadecyltriethoxy silane, and combinations thereof. Methods of synthesizing and using the nanoparticle composition are also provided. 1. A nanoparticle composition comprising: a core comprising tantalum oxide, and', 'a covalent coating covalently bound to the core, the covalent coating comprising a surface modifier selected from the group consisting of (3-aminopropyl)trimethoxy silane (APTMS), (3-aminopropyl)triethoxy silane (APTES), APTMS-methoxy-poly(ethylene-glycol)-succinimidyl glutarate (APTMS-m-PEG-glutarate), APTES-methoxy-poly(ethylene-glycol)-succinimidyl glutarate (APTES-m-PEG-glutarate), 2-[methoxy (polyethyleneoxy)-9-12-propyl]trimethoxysilane (PEG-Silane), fluorescein isothiocyanate (FITC)-APTMS, FITC-APTES, hexadecyltriethoxy silane, and combinations thereof., 'a plurality of nanoparticles, each nanoparticle of the plurality having2. The nanoparticle composition according to claim 1 , wherein the nanoparticle composition is in the form of a lyophilized powder.3. The nanoparticle composition according to claim 1 , wherein the tantalum oxide comprises TaO claim 1 , where 0 Подробнее

COMPOSITION FOR HEPATIC ARTERIAL CHEMOEMBOLIZATION USING HUMAN SERUM ALBUMIN NANOPARTICLES CARRYING ANTICANCER AGENT, AND METHOD FOR PRODUCING SAME

The present invention aims to dramatically increase the effect of hepatic arterial chemoembolization by developing human serum albumin-based nanoparticles, which are bioproteins that effectively carry Adriamycin in place of Adriamycin, an anticancer agent used in hepatic arterial chemoembolization. The human serum albumin nanoparticles carrying the Adriamycin not only intensively infiltrate the drug effectively into the cells but also have a synergistic effect that can induce a long-term therapeutic effect by utilizing the effect of continuous drug release from the particles. 119-. (canceled)20. A composition for hepatic arterial embolization comprising:an embolic material; andhuman serum albumin nanoparticles carrying a water-soluble anticancer agent.21. The composition of claim 21 , further comprising:microbubbles; andwherein, the human serum albumin nanoparticles bind to surfaces of the microbubbles.22. The composition of claim 20 , wherein the embolic material is lipiodol.23. The composition of claim 20 , wherein the water-soluble anticancer agent is selected from the group consisting of mitomycin claim 20 , cisplatin claim 20 , Adriamycin claim 20 , gemcitabine claim 20 , and a mixture thereof.24. The composition of claim 20 , wherein a volume ratio of the embolic material to the human serum albumin nanoparticles is 1:1 to 4:1.25. The composition of claim 21 , wherein a volume ratio of the embolic material to the microbubbles and the human serum albumin nanoparticles is 1:1 to 4:1.26. The composition of claim 20 , wherein a concentration of the water-soluble anticancer agent is 1 mg/mL to 20 mg/mL.27. The composition of claim 20 , wherein a concentration of the nanoparticles is from 10 mg/mL to 50 mg/mL.28. A method for preparing the composition of comprising:dispersing human serum albumin nanoparticles carrying a water-soluble anticancer agent in a computed tomography and X-ray contrast medium; andmixing the dispersed nanoparticles with an embolic material.29. ...

CONTRAST AGENT

According to one embodiment, a contrast agent includes a blood vessel contrast enhancement particles configured to enhance contrast of a blood vessel of an object and a diseased tissue contrast enhancement particles configured to enhance contrast of a diseased tissue of the object. The blood vessel contrast enhancement particles have a first particle size larger than a gap of vascular endothelial cells under an EPR effect. The diseased tissue contrast enhancement particles have a second particle size smaller than the gap. 1. A contrast agent comprising a blood vessel contrast enhancement particle configured to enhance contrast of a blood vessel of an object and a diseased tissue contrast enhancement particle configured to enhance contrast of a diseased tissue of the object , the blood vessel contrast enhancement particle having a first particle size larger than a gap of vascular endothelial cells under an EPR effect , and the diseased tissue contrast enhancement particle having a second particle size smaller than the gap.2. The agent of claim 1 , wherein the blood vessel contrast enhancement particle is chemically modified to be bonded to albumin in the blood vessel.3. The agent of claim 1 , wherein the diseased tissue contrast enhancement particle includes a ligand configured to be specifically bonded to the diseased tissue.4. The agent of claim 3 , wherein the diseased tissue is a cancer cell claim 3 , andthe ligand is configured to be specifically bonded to a protein existing on a surface of the cancer cell or inside the cancer cell.5. The agent of claim 1 , wherein the first particle size is larger than a standard value of a gap between vascular endothelial cells contained in an imaging target blood vessel in which an EPR effect is recognized.6. The agent of claim 1 , wherein the second particle size is smaller than a standard value of a gap between vascular endothelial cells contained in an imaging target blood vessel in which an EPR effect is recognized.7. The ...